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 During the embryonic development of the heart and the greater vessels, some 
malformations may occur that can result in congenital heart diseases (CHD). The 
incidence of CHDs is estimated to be between 8 to 10 in 1000 live births. They can be the 
result of an underlying genetic disorder, be related to environmental factors or a 
combination of both.  
 
CHDs may require corrective cardiac surgery in order to improve life expectancy. Due to 
clinical advances in the recent years, the survival rate of patients with congenital heart 
disease has improved significantly and it is estimated that by 2020 there will be 750,000 
people with congenital heart disease. 
 
Despite advances in cardiac surgery, the current techniques in protection of cyanotic 
myocardium during corrective cardiac surgery are not ideal. This is particularly relevant 
as these hearts sustain reoxygenation injury during cardiopulmonary bypass (CPB) 
using higher oxygen levels. We have hypothesised that cyanotic patients’ own oxygen 
levels during the corrective cardiac surgery could reduce myocardial and other organ 
injuries associated with reoxygenation insult. 
 
In order to test our hypothesis we randomised 79 cyanotic patients to receive either 
normoxic or hyperoxic cardiopulmonary bypass during their corrective cardiac surgery.  
Systemic inflammatory responses and organ specific insults were assessed by 
measuring serum troponin I, alpha glutathione S-transferase (aGT), protein S100, 8- 
isoprostane, complement activation C3alpha, cortisol, interleukins 6, 8 and 10. The 
blood samples were taken at anaesthetic induction, 10 and 30 minutes after initiation of 
CPB, plus 10min, 4 hours and 24 hours post cessation of CPB.   
We also performed a sub-analysis for cyanotic patients with double ventricular (n=47) 
and functional single ventricular pathology (n=32). 
 
In all 79 patients, normoxic cardiopulmonary bypass significantly (p<0.05) reduced 
markers of organ damage (troponin I, aGT and protein S100), oxidative stress (8-
isoprostane) and markers of inflammatory response (IL-6 and IL-8). In double 
 c 
ventricular patients, normoxic CPB resulted in lesser levels of aGT, protein S100, 8-
isoprostane, IL-10markers and cortisol. Single-ventricle patients who were randomised 
to receive normoxic CPB, had a significantly decreased levels of troponin I, aGT, protein 
S100, 8-isoprostane, C3a, IL-6, IL-8 and cortisol.  
 
Our results provided direct evidence of the beneficial effects of normoxic versus 
hyperoxic CPB on the heart, brain and liver as well as inflammatory and systemic stress 
response in cyanotic patients undergoing corrective cardiac surgery. These findings 
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 Patients with cyanotic congenital heart disease may have to undergo 
corrective cardiac surgery for the correction of their cardiac pathology. During 
this process these patients may undergo cardiopulmonary bypass (CPB) in order 
for the surgeon to be able to operate on the heart safely. The current common 
practice is to deliver the same level of oxygen to the cyanotic patients during CPB 
as it is delivered to acyanotic ones. 
 
One of the most important goals during cardiac surgery is protection of the heart 
(myocardial protection). However, the techniques for myocardial protection in 
paediatric cyanotic hearts are not ideal [1-4]. There is a large body of evidence on 
the effects of re-oxygenation injury in cyanotic paediatric patients undergoing 
corrective cardiac surgery [5]. It has been demonstrated that cyanotic children 
undergoing open-heart surgery suffer myocardial damage, assessed by the 
release of troponin-I [5] as well as an increase in the specific markers of organ 
dysfunction, particularly for very susceptible organs such as the brain [3, 5-7]. Modi 
et al studied, 29 children with or without hypoxic stress. They reported that 
cyanotic patients exhibited significantly higher levels of troponin-I release 
compared to acyanotic ones [5]. They proposed that this could be due to the initial 
introduction of relatively high levels of oxygen during CPB. This has been also 
suggested in other clinical studies [2, 4, 8]. 
 
Myocardial dysfunction, characterised by endothelial damage, reduces cardiac 
compliance, which subsequently leads to low output syndrome. This remains a 
leading cause of perioperative morbidity and mortality after successful repair of 
congenital heart defects [1, 4, 8, 9]. 
 
Cerebral dysfunction is also another major cause of mortality and morbidity after 
repair of congenital cardiac defects in infants and children [6, 7]. Subtle 
neurological and cognitive dysfunction may be evident even among children in 
whom cardiac repair is completely successful. Transient neurological 
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derangements immediately after CPB may occur in as many as 64% of patients 
when studied within 24 hours of surgery [6, 7]. 
 
Little is known on the effects of controlled re-oxygenation during CPB in children 
undergoing corrections of congenital cardiac abnormalities.  
 Studies of hypoxaemia-reoxygenation in immature piglets have provided 
evidence for oxygen-mediated myocardial injury as a result of hyperoxaemia in 
the setting of previous cyanosis [10]. The immature heart has a higher tolerance to 
hypoxia, but preceding hypoxia prior to ischaemic cardioplegic arrest results in 
poor functional recovery and is associated with derangement in several 
metabolites [11, 12]. Hypoxia also reduces the antioxidant reserve capacity, leading 
to a greater susceptibility to the oxidative stress of ischaemia (e.g. cross-
clamping of the aorta) and re-oxygenation [1, 4, 9, 11, 12]. Re-introduction of oxygen 
exacerbates this situation and eventually leads to a reduction in myocardial 
contractility. This is via the production of free radicals and subsequent lipid 
peroxidation, cell damage, mitochondrial dysfunction and enzyme leak [1, 4, 9, 13-
16].  
 
One of the strategies proposed to avoid this situation is the use of controlled re-
oxygenation. This involves starting CPB with a hypoxic prime, until normoxic 
reoxygenation is started. This has been shown to avoid reoxygenation injury and 
led to almost complete functional recovery [17, 18]. Ihnken et al showed the 
beneficial effects of normoxic reoxygenation in a clinical animal model of acute 
hypoxaemia [19]. The same authors demonstrated that hyperoxic CPB during 
cardiac operations in adults resulted in oxidative myocardial damage related to 
oxygen-derived free radicals and nitric oxide [20]. Reduced oxygen tension 
management can markedly limit these adverse effects.  
 
The concept of normoxic CPB can therefore be applied to surgical advantage 
during cardiac operations, especially in paediatric patients undergoing repair of 
complex cyanotic heart defects. Nevertheless, there is no clinical evidence 
showing the benefits of these surgical strategies during paediatric heart surgery. 




The heart is a vitally life-sustaining myogenic organ found in all animals 
with a circulatory system (including all vertebrates), and with repeated rhythmic 
contractions it pumps blood throughout the blood vessels. In an adult human, on 
average, the heart weighs 250 to 300 grams in females and 300 to 350 grams in 
males and it is roughly about the size of the individual’s fist. It is estimated that 
in an average adult, the heart pumps more than 6000 litres of blood daily 
through the body and it beats more than three billion times over the course of 
their life [21-23]. 
 
The heart is principally composed of cardiac muscle (involuntary striated muscle 
tissue found in this organ only) plus connective tissue. Its blood supply is from 
coronary circulation and a double-walled sac called the pericardium encloses it. 
This sac shields the heart, anchors its surrounding structures, and prevents it 
from overfilling with blood [23, 24].  
 
Mammalian heart has a complete division into two pumps known as right and 
left heart [25]. The function of the right heart is to collect less oxygenated blood 
from the body (via inferior and superior vena cavae as well as the coronary 
sinus) and send it into the lungs (pulmonary circulation) so that carbon dioxide 
can be exchanged for oxygen (gas exchange). The left heart receives oxygen rich 
blood from the lungs and pumps it out to the rest of the body (systemic 
circulation) (Figure 2). 
 
Sometimes malformations during embryonic development can lead to congenital 
heart diseases (CHD). Congenital heart diseases are described as abnormalities of 
the cardiocirculatory structure or function that exist at birth, even if it is 
discovered much later [26, 27]. Congenital cardiovascular malformations usually 
result from altered embryonic development of a normal structure or failure of 
such structure to progress beyond the early stage of embryonic or foetal 
development [27].  
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The true incidence of congenital cardiovascular malformations is difficult to 
accurately determine, however it is estimated that between 8 to 10 in 1000 live 
births are complicated by a cardiovascular malformation [26, 27]. Nevertheless, it is 
important to bear in mind that these figures do not take into account what may 
be the two most common congenital cardiac anomalies; the congenital, 
functionally normal bicuspid aortic valve and prolapse of the mitral valve [26].  
CHDs can occur with Mendelian inheritance directly as a result of a genetic 
abnormality, be strongly associated with an underlying genetic disorder (e.g., 
trisomy), be related directly to the effect of an environmental toxin (e.g., alcohol), 
be associated with infections (e.g. rubella), or result from an interaction between 
multifactorial genetic and environmental influences [27].  
 
Congenital heart diseases can be categorised into cyanotic and acyanotic. 
Cyanotic patients have a lower than normal arterial oxygen saturation and may 
present with blue appearance of the skin and mucous membranes, however 
acyanotic patients, have normal arterial oxygen saturation. In principal, 
malformations causing a left to right shunt are acyanotic and malformations 
causing right to left shunt are cyanotic CHDs. 
 
Despite advances in cardiac surgery, the current techniques in protection of 
cyanotic myocardium during corrective cardiac surgery are not perfect [8, 28]. This 
is particularly relevant as these hearts sustain reoxygenation injury during 
cardiopulmonary bypass (using normal oxygen saturation) and prior to 
cardioplegic arrest [5]. We have hypothesised that cyanotic patients’ own oxygen 
levels during the corrective cardiac surgery could reduce myocardial and other 
organ injuries associated with reoxygenation insult and optimise the outcome of 
surgery.  
 
It is important to have an understanding of cardiac anatomy, development and 
physiology to apprecitate the cyanotic heart. This chapter presents a brief 
description of cardiac anatomy, embryology and some cyanotic cardiac 
anomalies as well as the physiology of the heart. At the end of this chapter, the 
principle of cardiopulmonary bypass will be dicussed. 
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1.3 Anatomy of the heart and it’s development 
 
The heart is situated in the thoracic cavity in the middle mediastinum. It is 
a muscular organ that is hollow and somewhat pyramidal in shape. It is 
ensheathed in a sac called pericardium. Pericardium encloses the heart and the 
roots of the great vessels. At its base, the heart is connected to the great blood 
vessels and otherwise sits free within the pericardium. It has three surfaces: 
anterior, posterior and inferior. A normal heart has four chambers: two atria and 
two ventricles plus four valves. These valves work as a one-way passage for 
blood to flow from the atria to the ventricles and from the ventricles to the main 
vessels exiting the heart, called the aorta and the pulmonary trunk  (Figure 1).   
 
Figure 1 Chambers of the heart  
(Image from www.umm.edu, University of Maryland Medical Centre) 
 
 
Although the cardiac atria and ventricles are positioned posteriorly and 
anteriorly, due to their primary embryological positions they are referred to as 
right and left atria and ventricles [23]. The right atrium and right ventricle (also 
known as the right heart) form part of the heart that receives the venous 
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drainage that has a lower level of oxygenated blood and pumps it to the 
pulmonary circulation. During this process blood is oxygenated in the lungs. The 
left atrium and left ventricle (also known as the left heart) receive the 
oxygenated blood from the lungs and pump it into the systemic circulation to 
provide oxygen and nutrients to the body (Figure 2). 
 
Figure 2 Blood Circulation  




The process that heart fills with blood and empties is referred to as the cardiac 
cycle[23]. In a normal adult, the heart beats between 60 to 100 times per minute at 
rest and in the new-born between 110 to 150 [29]. This rate can increase during 






1.4 Embryological development of the heart 
 
 During the initial 20 days of development, the human embryo lacks 
cardiovascular structure. Over the following 4 weeks, the development is almost 
completed and the appearance is very similar to that at full gestation. During this 
process isolated angiogenic cell islets are transformed into a complex four-
chambered structure and by the 28th day blood circulation through the embryo 
commences [30]. 
 
Embryologically, the heart derives from the lateral mesodermal layer [30]. Initially 
clusters of cells arise in the mesenchyme. These clusters of cells form a plexus of 
endothelial blood vessels that fuse to form the right and left endocardial heart 
tubes. The first indication of any cardiovascular development occurs on 
approximately day 18 or 19. The right and left endocardial heart tubes soon fuse 
to form a single median endocardial tube. The heart tube then starts to bulge into 
the pericardial cavity and the primitive heart is established. It has been reported 
that when heart is cultured in vitro, the heart will loop even when the pericardial 
sac is removed [31]. The process of looping is therefore thought to be a genetic 
property of the myocardium and not related to differential growth. 
 
The heart begins to beat soon after the 3rd week of gestation but the circulation 
does not start until the 4th week [23]. The heart tube then undergoes differential 
expansion so that several dilatations result: the bulbus cordis (the distal part of 
bulbus cordis is known as truncus arteriosus), the ventricle, the atrium plus the 
right and left horns of sinus venosus (Figure 3). Outside the caudal end of the 
pericardial sac, lay the primitive atrium and sinus venosus and outside the 
cranial end of the pericardial sac, lay the truncus arteriosus. Some publications 
however support the use of inlet, outlet, and arterial segments as proposed by 




Figure 3 Heart tube differentiation 
(Image from www.ans.iastate.edu, Iowa State University) 
 
The tube then begins to bend in an S shape manner with the atrium lying 
posterior to the ventricle (Figure 4). Tumour growth factor β (TGF β) and 
vascular endothelial growth factor (VEGF) signalling have been implicated in this 
event [35, 36]. 
 
Figure 4 Heart tube bends in an S shape form, placing atria posteriorly and ventricles anteriorly 
(Image from www.ans.iastate.edu, Iowa State University) 
 
Sinus venosus develops into the veins and some parts of the atria and the 
truncus arteriosus develops into the aorta, pulmonary trunk and some parts of 
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the ventricles. In the middle of the sinus venosus and truncus arteriosus, the 
heart tube develops into the remaining part of the heart [23].  
 
During the fifth to eighth week of development, the atrioventricular valves are 
formed [37]. Initially, at the atrioventricular junction, the endocardial cushion 
tissue forms bulges. These bulges have the appearance of valves, and although 
they may play a significant part in the final construction of the atrioventricular 
valves, endocardial cushion tissues are not the precursors of the mitral and 
tricuspid valves [38]. A fraction of epicardial cells invades the underlying 
myocardium which give rise to atrioventricular valve tissue, cardiac fibroblasts 
and endothelial plus smooth muscle cells of the coronary vessels [39]. Coronary 
vascular network is formed from the epicardium [40].  
 
As the heart continues to develop, atrial septation starts when the common 
atrium becomes indented externally by the bulbus cordis and truncus arteriosus. 
Internally, this indentation corresponds with a thin sickle-shaped membrane 
developing in the common atrium on day 35 [34]. This membrane later divides the 
common atrium into left and right atria. This membrane is known as the septum 
primum. The space between the septum primum and the endocardial cushion is 
known as the foramen primum. It is important to appreciate that the foramen 
primum is not a hole in the septum primum but rather a space or a gap between 
the septum primum and the endocardial cushion. 
As the septum primum continues to grow towards the endocardial cushion, 
during a programed cell death (apoptosis) an opening is made in the septum 




Figure 5 Atrial septation 
(Image from www.alfaisaldoctors.com) 
 
These foramens allow blood to travel from the right side of the heart to the left. 
This is vital for the infant since they do not breathe and all the oxygenated blood 
from the mother comes to the right atrium (Error! Reference source not 
found.). Meanwhile, another sickle-shaped membrane known as septum 
secondum develops on the anterosuperior wall of the right atrium, just right to 
the septum primum and left of the sinus venosus valve. Its development halts 
when it has just gone past the foramen secondum. The septum secondum is 
thicker and more rigid than the septum primum. The pressure in the right atrium 
forces the septum primum to be pushed away from the septum secondum. This 
creates an opening known as foramen ovale (named after its oval shape). 
In the meantime a muscular ridge grows from the apex of the embryonic 
ventricle towards the aorticopulmnary septum. This muscular ridge is the 
embryonic ventricular septum. The aorticopulmonary septum, also known as the 
spiral septum, is a septum that divides the truncus arteriousus longitudinally. It 
is referred to as spiral septum because during its development it twists around 
its axis, which will lead to placing the aorta on the left and the pulmonary trunk 





Figure 6 aorticopulmonary septum dividing truncus arteriousus into aorta and pulmonary trunk whilst 
twisting 180 degrees around its axis 
(Image from Clinical Anatomy by Snell, 7th edition [23]) 
 
 
The part of the ventricular septum that is made from the embryonic ventricular 
septum is referred to as the muscular inter-ventricular septum and the part that is 
made from the aorticopulmonary septum is known as membranous intra-
ventricular septum [30]. 
 
After birth once the baby starts to breathe, the resistance in the pulmonary 
artery drops as well as the right atrial pressure. This results in a higher pressure 
in the left atrium than the right. This higher pressure pushes the septum primum 
towards the septum secundum, which leads to the closure of the foramen ovale. 
 
At times, during the embryonic development of the cardiovascular system, 
variations can occur that may lead to congenital heart defects. 
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Figure 7 Foetal circulation 




1.5 Congenital Heart Defect (Disease) 
 
 
 During the embryonic development of the heart and the greater vessels, 
some malformations may take place that may result in congenital heart diseases 
(CHD). Most such disorders arise from faulty embryogenesis during gestational 
week 3 thorough 8, when the major cardiovascular structures develop [41]. 
Although all causes of CHD are not entirely known to us, factors such as 
environment (for example, congenital rubella infection) and genetics (familial 
forms of CHD, chromosomal abnormalities such as certain mutations, trisomies 
13,15,18 and 21 plus Turner syndrome) are known to have an association with 
CHD [41]. 
 
The incidence of CHD has been reported to be approximately between 0.8 to 1% 
of live births. This incidence however, can be higher in premature infants [42]. 
Congenital heart diseases can be categorised into cyanotic and acyanotic [41, 43, 44]. 
Fundamentally, malformations causing a left-to-right shunt are acyanotic and 
malformations causing right-to-left shunt are cyanotic CHD. The most common 
congenital cardiac anomaly at birth is ventricular septal defect (VSD) followed by 
atrial septal defect (ASD) [41]. However VSD and ASD are both acyanotic 
conditions as the shunt is left-to-right. Cardiac malformation associated with 
right-to-left shunts, are distinguished by cyanosis at, or near, the time of birth [41, 
43, 44]. 
 
Due to clinical advances in the recent years, the survival rate and life expectancy 
of patients with congenital heart disease has improved significantly [45]. In fact, it 
is estimated that by 2020 there will be 750,000 people with congenital heart 




1.5.1 Cyanotic Congenital Heart Defects (Disease) 
 
 
 Cyanotic conditions or blue baby syndrome can be caused by a right-to-left 
shunt or malposition of the great arteries [44]. Cyanotic drives from the Latin 
word cyano, which means blue. The skin or mucous membranes of these patients 
may appear purple or blue (cyanotic), due to deoxygenated blood bypassing the 
lungs and entering the systemic circulation. 
Some of the congenital cardiac conditions that can cause cyanosis are described 
below: 
1.5.1.1 Tetralogy of Fallot:  
 
Tetralogy of Fallot is the most common cyanotic cardiac defect and accounts for 
about 5% of all congenital cardiac malformation [46] with an incidence of 3.26 per 
10,000 live births, per year [47-49]. In this malformation the division of the truncus 
arteriosus does not take place at the middle which then leads to: infundibular 
pulmonary stenosis, a conoventricular septal defect, dextroposition of the aorta 
so that the aortic root overrides the crest of ventricular septum, and 
subsequently right ventricular hypertrophy (Figure 8). This combination of 
anomalies was described in detail by Fallot in 1888 [50]. In addition to these four 
defining features, there may be pulmonary valve atresia. This is known as 
tetralogy of Fallot with pulmonary atresia, previously called truncus arteriosus 
type IV or pseudotruncus. It represents approximately 20% of all tetralogy of 
Fallot patients. 
Patients with Tetralogy of Fallot are cyanotic due to right-to-left shunting at the 
ventricular level. This occurs because the anatomic right ventricular outflow 
tract obstruction causes a rise in pressure that exceeds the systemic vascular 
resistance. Under these circumstances, the oxygen-poor blood in the right 
ventricle shunts across the defect into the left ventricle and from there into the 
systemic arterial circulation. 
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Mutations in several human genes have been identified in Tetralogy of Fallot, 
NKX2.5[51], JAG1[52, 53], TBX5[54], FOXC2[55].  Deletion of human TBX1 
appears to be the basis for the 15% of Tetralogy of Fallot attributable to 
chromosome 22q11.2 micro-deletion, although TBX1 mutations in non-deleted 
tetralogy of Fallot patients remain to be identified [56-58]. 
 
Figure 8 Tetralogy of Fallot 
(Image from www.theheart.org) 
 
1.5.1.2 Transposition of the Great Arteries (vessels) or TGA:  
 
The second most common cyanotic congenital cardiac defect encountered in 
early days after birth is transposition of the great arteries. It is one of the major 
reasons for admission to a cardiac unit in the first two weeks of life [59]. In this 
condition, the natural rotation of the truncus arteriosus around its axis does not 
take place. This then leads to the aorta exiting from the right ventricle and the 
pulmonary trunk from the left ventricle (Figure 9). In utero this may not cause 
problems, however, this is incompatible with life after birth. Therefore for the 
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new-born with TGA to be able to survive, she/he has to have either a patent 
ductus arteriosus, a patent foramen ovale, a VSD or a combination [60]. 
 
Remarkably, the number of children born each year with TGA (∼0.24/1000 live 
births) is constant compared to other congenital cardiac defects. This constancy 
may be due to an easy diagnosis in early infancy [59]. There is no data to link an 
identified genetic abnormality to explain the existence of TGA. Recurrence in the 
same family is virtually unrecognised. There are fewer extracardiac anomalies 
associated with TGA when compared to most other congenital cardiac defects, in 
fact, possibly fewer than the general population [61]. Furthermore, there is a 
smaller incidence of TGA among premature infants and those with low birth 
weights [61, 62].  However there are reports that advanced maternal age and higher 
birth order can be associated with higher incidence of TGA [62]. 
50% of the infants with TGA present with ventricular defects at birth, but in the 
first one year this number is reduced to one third due to spontaneous closure [63]. 
Additional cardiac anomalies are more common amongst children with 
transposition of the great arteries and ventricular septal defect compared to 
ones with transposition of the great arteries and intact ventricular septum. Thus, 
in the presence of ventricular septal defect, it is more likely to encounter 
pulmonary stenosis, pulmonary atresia, an overriding or straddling 
atrioventricular (AV) valve, coarctation of the aorta, and interruption of the 
aorta. However right ventricular outflow obstruction is uncommon [64]. 
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Figure 9 Transposition of Great Arteries 
(Image from www.childrenshospital.org, Boston Children’s Hospital) 
1.5.1.3 Total Anomalous Pulmonary Venous Connection (TAPVC):  
 
Also known as total anomalous pulmonary venous drainage (TAPVD) or total 
anomalous pulmonary venous return (TAPVR), is another form of cyanotic CHD in 
which there is a malposition of all four pulmonary veins that leads to their 
abnormal connections to the systemic venous circulation.  
Normally by the end of the first month of the embryological phase, lung buds 
have developed within the splanchnic plexus. The splanchnic plexus has 
numerous connections with the cardinal and omphalovitelline systems. Shortly 
after, a common pulmonary vein appears that connects the sinoatrial portion of 
the heart to the pulmonary venous plexus, and later incorporates into the left 
atrial wall, by which time the pulmonary–splanchnic venous connections have 
disappeared [65]. When the common pulmonary vein fails to unite with the left 
atrium, there may be some persistency in pulmonary–splanchnic venous 
connections. This allows pulmonary venous return at various systemic venous–
right atrial levels, such as the left innominate, portal, and coronary sinus levels. 
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Various combinations of pulmonary vein(s) draining anomalously into the 
systemic venous or right heart circulation may result in left-to-right shunt. The 
patient is said to have TAPVC, if all pulmonary veins drain into the systemic 
venous circulation. There may be variable, absolute, or relative obstruction of the 
pulmonary venous system [66, 67]. In the presence of obstruction, there is 
pulmonary venous hypertension and reactive pulmonary arterial hypertension, 
which can often be above the systemic pressure. 
 
It is reported that amongst critically ill infants, isolated TAPVC is the 12th most 
common cardiac defect (0.056 per 1000 live births), constituting 2.6% of the 
total prevalence [47, 61, 68]. Other simple cardiac anomalies, such as ventricular 
septal defect, may rarely be associated with total anomalous veins; however, 
major cardiac abnormalities are more likely to be present when there is asplenia 
and polysplenia 
 
There are four TAPVC variants: 
  
 Supracardiac: All pulmonary veins drain to the common pulmonary vein 
behind the left atrium, which then drains upward on the left side of the 
chest, usually in front of the pulmonary artery, into the left 
brachiocephalic (innominate) vein. Occasionally the common pulmonary 
venous channel drains directly into the superior vena cava and sometimes 
into the azygous system. 
 
 Cardiac: All pulmonary veins drain into the common pulmonary vein and 
subsequently into the right atrium or, more often, into the coronary sinus. 
 
 Infradiaphragmatic: Once pulmonary veins drain into the common 
pulmonary vein behind the heart, it passes down a venous channel 
through the diaphragm to the portal vein, ductus venosus, or hepatic vein, 
re-entering the heart through the left inferior vena cava. 
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 Mixed: Is a mixture of the above. For pulmonary veins to drain into the 
venous circulation, any anatomical combination is possible. For example, 
right atrium may receive the right-sided veins and the left veins to drain 
into the left innominate. 
 
 
Following information gathering from large surgical series, the pulmonary 
venous return sites were reported as; 49% supracardiac, 25% cardiac, 18% 
infradiaphragmatic, and 8% mixed [69-73].  
 
1.5.1.4 Hypoplastic Left Heart Syndrome (HLHS): 
 
In this form of cyanotic CHD there is a diminutive left ventricle with 
underdeveloped mitral and aortic valves [74]. The prevalence varies between 0.21 
and 0.28 per 1000 live births [42, 59].  
 
Although some babies may present with severe aortic stenosis, usually there is 
hypoplasia or atresia of the aortic valve. Similarly, the mitral valve may be 
hypoplastic, severely stenotic or atretic (Figure 10). As the left ventricle is too 
small, it is unable to support the systemic circulation, therefore both pulmonary 
and systemic circulation will rely on the right heart. For a period, the right 
ventricle may be able to cope to support the circulation to both the lungs and the 
body, but if left untreated, this extra workload will eventually lead to heart 
failure.  
 
As in most forms of congenital heart disease, the intrauterine circulation is 
adequate to meet the needs of the developing foetus in the hypoplastic left heart 
syndrome and to support normal intrauterine growth. However a patent ductus 
arteriosus (PDA) with or without an ASD must be present for the newborn to be 
able to survive after birth.  
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Aortic coarctation is a common finding amongst survivors following surgical 
intervention, however autopsies of untreated infants rarely show coarctation of 
the aorta. This suggests that there is an intrinsic tendency to develop coarctation 
in this anomaly [75, 76]. Hypoplastic left heart syndrome may also be associated 
with some cerebral anomalies [77]. 
 
Figure 10 Hypoplastic left heart 
(Image from www. mediocritycodex.blogspot.co.uk)  
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1.5.1.5 Persistent Truncus Arteriosus (PTA): 
 
Also known as Common Arterial Trunk (CAT), PTA is characterised by 
origination of a solitary arterial vessel from the heart, overriding the ventricular 
septum, and supplying the systemic, pulmonary and coronary circulations from 
the proximal ascending vessel. Reported incidence of PTA rates from 0.006 to 
0.043/1000 live births [78, 79] and there is a well-recognised association with 
DiGeorge syndrome and deletion of chromosome 22q11 [80]. 
In the normal embryo, by the end of the fifth week, septation of single truncus 
arteriosus occurs, resulting in aorta and main pulmonary artery as well as 
formation of aortic and pulmonary valves. Soon after, the formation of conal 
septum is complete. Through these weeks, developmental disturbances can 
result in conotruncal abnormalities including truncus arteriosus [81-83].  
For one to confidently diagnose the true truncus arteriosus, no remnant of a 
separate main pulmonary artery connected to the heart should be present and 
there must be no evidence of a separate pulmonary valve.  
 
 
It is very rare for the truncal valve to be found normal and it often has deformed 
and thickened leaflets (72%) [84] which are variably stenotic or, more often, 
incompetent (50%) [85]. The number of leaflets can vary. In a literature review by 
Fuglestad et al, 21% quadricuspid, 69% tricuspid, 9% bicuspid, and 1% 
unicuspid were reported [85]. In almost all patients with PTA, ventricular septal 
defect is present, which is normally not small. Other conditions such as 
interrupted aortic arch (11-14%) [84] and extracardiac anomalies (21-48%) [61, 84] 





1.5.1.6 Tricuspid Atresia: 
 
The characteristics of this cyanotic CHD are the absence of the tricuspid valve 
plus right ventricular hypoplasia. Tainer et al. have reported a frequency of 0.057 
per 1000 live births [61]. 
 
As there is a lack of an A-V connection, in order to maintain blood flow, an ASD as 
well as a VSD must be present since the right ventricle is hypoplastic. A PDA is 
usually present to increase pulmonary flow. 
 
Conventionally, patients with tricuspid atresia are divided into 3 groups: 
 
Type I: those without transposition of the great arteries, 
Type II: those with transposition of the great arteries, 




In these patients, blood passes from the right atrium to the left atrium through 
an atrial septal defect or, more often, a patent foramen ovale and from there to 
the left ventricle. In most cases there is no indication that a valve was ever 
present or that there was an alignment of atrium towards the right ventricle [86].  
These patients all have small right ventricles and in some cases, the right 
ventricle is no more than a channel connecting the left ventricle to the 
pulmonary artery. 
A common finding is aortic coarctation, particularly in type II (about 33%). Some 
other cardiac anomalies also occur amongst both types I and II such as; right 
aortic arch, left juxtaposition of the atrial appendages, persistent left superior 




1.5.1.7 Interrupted Aortic Arch (IAA): 
  
This is a very rare form of CHD affecting 3 per million live births [89]. The 
characteristic of this anomaly is the loss of luminal continuity between the 
descending and ascending segment of the aorta. By enlarge, IAA is associated 
with intracardiac malformations such as VSD, PDA, bicuspid aortic valve, left 
ventricular outflow tract obstruction, or aortopulmonary window. There are 3 
types of IAA. Type A, where aortic arch discontinuity is distal to the left 
subclavian artery, type B, where the discontinuity is between left subclavian and 
the left carotid arteries and type C, where the discontinuity lies between left 
carotid and the innominate arteries. The most common type is B (53%), followed 
by A (43%) and C (4%) [90]. This condition is also often associated with DiGeorge 
Syndrome.  
 
1.5.1.8 Pulmonary Atresia:  
 
This form of CHD is characterised by complete obstruction of right ventricular 
outflow plus a variable hypoplasia of the right ventricle and tricuspid valve. The 
pulmonary valve cusps are obstructed with a layer of tissue resulting in no blood 
flow to the lungs via the pulmonary trunk. This condition is not life threatening 
during the intrauterine period, however following birth the baby will be 
cyanotic. Pulmonary atresia can exist in the presence of a VSD or an intact 
ventricular septum. In the latter a PDA would be the only source of pulmonary 
blood flow.  
 
The incidence rate has been reported as 0.040 and 0.045 per 1000 live births, 
with some resent decline possibly due to termination of pregnancy [91, 92]. 
 
There are strong suggestions that pulmonary atresia in the presence of intact 
ventricular septum is an acquired disease rather than abnormalities related to 
embryological development. Supporting evidences for this theory include; large 
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pulmonary arteries despite little pulmonary blood flow, frequent findings of 
well-formed valve leaflets despite being fused, lack of arterial collaterals to the 
pulmonary circulation, a right ventricle that can vary in size, rare associations to 
extracardiac anomalies and anatomical similarities to newborns with critical 
pulmonary valve stenosis [91].  
 
Abnormalities of coronary artery are as common as 70% at angiography [65, 93-95] 
however associated extracardiac anomalies are uncommon. 
 
If left untreated, with closure of the ductus arteriosus in the first few days of life, 
survival will no longer be possible. 
1.5.1.9 Double-Inlet Ventricle 
 
Another form of cyanotic CHD is double-inlet ventricle. This condition is 
characterised as the presence of two atrioventricular valves with either, only one 
ventricular chamber, or a large dominant ventricle accompanied by a miniscule 
opposing ventricle [96-98]. 
 
The incidence is reported to be in around 1.25% of infants with congenital heart 
disease [99]. 
 
During the early stages of embryologic life, the atrioventricular canal unites with 
the ventricular part of the primitive heart tube, which during later stages this 
becomes the left ventricle. Blood passes from the ventricular portion of the 
primitive heart tube to the bulbus cordis, which later contributes to the right 
ventricular development. An arrest or a defect in interventricular septation 
results in a double-inlet single left ventricle with an underdeveloped right 
ventricle outflow chamber [98].  
 
Trabeculation characteristic as well as the anatomical position of the 
atrioventricular valves can be used to identify whether the chamber of a single 
ventricle heart is most like a left or a right ventricle.  
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Infants with single ventricle and pulmonary atresia are cyanotic at birth. The 
amount of pulmonary blood flow provided by ductus arteriosus, persistent 
aortopulmonary collaterals, or bronchial circulation determins the degree of 
cyanosis in these patients. Patients with severe pulmonary stenosis are 
comparable to those with pulmonary atresia and their clinical presentation is 
determined by the amount of pulmonary blood flow, which is limited by 
pulmonary stenosis or raised pulmonary vascular resistance. In the absence of 
pulmonary stenosis and falling foetal pulmonary vascular resistance, there will 
be a gradual increase in pulmonary blood flow, which can ultimately cause 
congestive heart failure. A small number of patients with pulmonary blood flow 
limited to about double the systemic blood pressure may do well for several 
years and despite their noticeable cyanosis, have a normal growth. 
 
The commonest form of double-inlet ventricle is a single left ventricle with L-
transposition of the great arteries and accounts for the 74% of autopsied cases 
[98]. In this form, aorta arises from a minute leftward right ventricle, pulmonary 
artery usually ascends posteriorly, mitral valve is on the right side and the 
tricuspid valve to the left. Holmes heart is are and another form of double-inlet, 




1.6 Cardiac Physiology 
1.6.1 Physiology of the developed Heart 
1.6.1.1 Contraction: 
Mammalian cardiomyocyte Contraction is a broadly studied subject [100-102]. 
Depolarisation of cardiomyocyte membrane initiates with an action potential. 
This prompts the entry of Ca2+ in the cardiomyocyte through L-type calcium 
channels. As a positive feedback result, Ca2+ is further released from the 
sarcoplasmic reticulum (SR) into the cytoplasm. Once there is a rise in the free 
intracellular Ca2+, Calcium ions bind to troponin-C. Troponin-C is then attached to 
the contractile filaments of actin and is part of a regulatory complex. Upon the 
binding of Ca2+ to troponin-C, tropomyosin disengages from the actin-binding 
site. This facilitates the actin to bind the myosin ATPase placed on the myosin 
head. This results in hydrolysis of ATP that provides energy for a conformational 
change to take place in the actin-myosin complex. All these changes lead to a 
movement between the myosin head and the actin, in a way that the actin and 
myosin filaments slide past each other thus shortening the length of the 
sarcomere, resulting to cell contraction. Then the intracellular Ca2+ is shifted 
back to the SR or released outside the cell via the sodium/calcium exchanger 
(NCX). Upon the reduction of intracellular Ca2+ concentration, tropomyosin 
returns on the actin; which results in termination of contraction and ultimately 
the cardiomyocyte relaxes [102]. 
A large number of proteins that play a major role in cardiac physiology are Ca2+ 
sensitive. These include classical protein kinases C (PKC α, β, and γ), ryanodine 
receptors (RyR), SR Ca2+ ATPase (SERCA), and phospholamban [103, 104]. It has been 
described that disturbed Ca2+ handling can be responsible for contractile 





In a healthy heart, the main source of energy is delivered by fatty acids. This 
accounts up to 80% of the entire energy (Figure 11). The rest of the energy is 





Figure 11 Cardiac energy production 




Normally, metabolism of myocardium is aerobic. Throughout normal 
physiological conditions, mitochondrial oxidative phosphorylation supplies more 
than 95% of the ATP production in the heart. Mitochondrial oxidative 
phosphorylation provides energy from electron transfer. These are transferred 
by dehydrogenation reactions that generate nicotinamide adenine dinucleotide 
hydrogen (NADH) and flavine adenine dinucleotide dihydrogen (FADH2).  
NADH and FADH2 are primarily produced via the fatty acid β-oxidation pathway, 
the citric acid cycle (or Krebs cycle), and to a lesser extent from the pyruvate 
dehydrogenase reaction [106]. Approximately 60-70% of the ATP produced is 
used for the contraction. The remaining 30-40% is used by the 
sarco(endo)plasmic reticulum calcium-ATPase (SERCA) and other ion pump 
transport [106]. Figure 12 illustrates a summary of interactions between different 




Figure 12 Different pathways of myocardial metabolism.  
CPT-I= carnitine palmitoyltransferase-1; FAT= fatty acid transporter; G 6-P= glucose 6-
phosphate; GLUT= glucose transporter; MCT= monocarboxylic acid transporters; PDH= 
pyruvate dehydrogenase; TG= triglycerides. 
(Reillustrated image from Lopaschuk et al, American Heart Association [107]) 
 
 
As demonstrated in Figure 12, throughout the fatty acid metabolism, a fatty acid 
transporter (FAT) facilitates the entry of fatty acids to the cardiomyocytes. When 
the fatty acids have been transported across the SR, they become activated by 
esterification. Then, in the mitochondria, fatty acid β-oxidation occurs, which 
leads to the production of NADH+, FADH2, and acetyl-CoA. Acetyl-CoA is then 
degraded during the citric acid cycle and results in ATP production. During the 
carbohydrate metabolism, glucose enters the cell, which then converts to glucose 
6-phosphate and degrades to pyruvate. In aerobic conditions, Pyruvate converts 
to Acetyl-CoA in the mitochondria. During the citric acid cycle, acetyl-CoA gets 
degraded, and this leads to energy production [106]. It is worth noting that 
Creatine phosphate is another source of energy for cardiomyocytes In addition to 
ATP [106]. 
 31 
1.6.2 Physiology of the Developing Myocardium  
 
1.6.2.1 Changes in Myocardial Structure During Postnatal Development: 
 
The structural and morphological changes to myocardium after birth have been 
extensively studied in animal models [108].  
After birth, the body rapidly grows. In accordance to this, the heart also needs to 
grow in weight and size in order to comply with increasing demands of a rapidly 
growing body. Johnson et al showed that the weight of rat’s heart increased 5-
fold in the first 11 days after birth [109]. Hyperplasia in heart ceases 4 days after 
birth and from this point onwards heart’s growth is a result of hypertrophy 
rather than hyperplasia [110, 111]. This transition from hyperplastic to 
hypertrophic growth is caused by a blockage of further mitosis [112]. 
 
The heart of a neonate in comparison to an adult contains more water, more 
non-contractile proteins and less collagen. This results in a less compliant 
neonatal myocardium when compared to an adult myocardium [113, 114]. 
Moreover neonatal cardiomyocytes exhibit disorganised myofibrils that are 
mainly found at the cell periphery. With age, myofibrillar organisation occurs, 
making the function of myocyte more efficient by allowing extracellular Ca2+ to 
enter the cell and rapidly target the contractile proteins to allow cell contraction 
[115].  
Intracellular Ca2+ stores in the neonatal cardiomyocytes are not fully developed, 
and as a result, the immature myocardium requires a higher extracellular Ca2+ 
concentration to optimise its contractility [116]. In rat experimental models, it was 
discovered that, under normal conditions the neonatal mitochondrial uptake of 





1.6.2.2 Postnatal Cardiac Development and Metabolism: 
 
Fisher and co-workers demonstrated higher oxygen consumption in neonatal 
lamb cardiomyocytes when compared to foetal and adult cardiomyocytes [118]. 
This mirrors the changes in cardiac output for these particular age groups, with 
increased cardiac pump function associated with cardiac development [119]. 
 
The developing heart undergoes a metabolic transformation as it changes from 
an anaerobic intrauterine to an aerobic extrauterine environment. After birth 
there is an increase in fatty acid metabolism whilst glycogen and lactate 
concentrations declines [120]. Neonatal cardiomyocytes have higher glycogen 
content when compared to the adult cardiomyocytes, which declines remarkably 
between 7th and 14th day post birth, indicating increasing reliance on glycolysis. 
The tolerance to the anaerobic environment during embryogenesis begins to 
decrease after birth.  
 
In the embryonic phase, the mitochondrial conversion of fatty acids to energy is 
noticeably lower than that of an adult. The embryonic development of the heart 
takes place in an environment that is relatively hypoxic and during this period, 
the embryo relies heavily on glycolysis for ATP production [121]. Glycolysis 
requires less oxygen to produce ATP and therefore it is favourable to the 
immature heart muscle [121]. 
 
Neonatal cardiomyocytes have a lower ability of aerobic ATP production 
comparing to the adult cardiomyocytes. As the mitochondrion matures, aerobic 
and oxidative metabolism capacity intensifies [122]. Several enzymes that are 
associated with the citric acid cycle and respiratory chain have been found to be 
low in activity in neonatal hearts, but as the cardiomyocytes adapt to the aerobic 
environment, the activity of these enzymes surges [123]. Throughout the postnatal 
period, the mitochondria continue to develop and increase in number and 
volume until they reach the maximal adult number [124]. 
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Cardiomyocyte mitochondrial Ca2+ capacity changes throughout postnatal 
development. Bassani et al showed an increased capacity of Ca2+ within the 
mitochondria via the Ca2+ uniporter in neonatal rat cardiac mitochondria. They 
also reported a decline in this capacity after the first 2 weeks of birth [117].  
 
1.6.2.3 Variance in Antioxidant Status During Developmental Period: 
 
Das et al demonstrated in their study that the antioxidant defence system in pigs 
undergoes developmental changes in the early phases of neonatal growth with 
minimal changes afterwards [125]. However, so far this finding has not been 
demonstrated in human or any other animal studies. Work on rat heart indicates 
changes that continue to take place beyond post-neonatal stage. Xanthine 
oxidase activity increases from birth to 16th week of age in the rat heart [126]. 
Xanthine oxidoreductase activities in adult rats are found to be significantly 
higher when compared to the new-born [127]. 
As well as adult cardiomyocytes, there is an upregulation of neonatal 
antioxidants during stressful conditions. Following exposure of cultured 
neonatal heart cells to non-lethal doses of hydrogen peroxide, a significant 
upregulation of catalase activity and mRNA expression was generated without 
having effects on SOD or GPx levels/activity [128]. 
 
1.6.2.4 Postnatal Development and Mechanism of E-C Coupling: 
   
In rat models following birth, the ventricular contractility index (an indicator of 
contractility which implicates wall stress, cell shortening and the force of 
contraction) substantially increases in the first week of life. In addition to this, as 
the heart develops and matures, the ventricular function noticeably increases 
[119]. The contractile response to a low Na+ concentration differs from day-to-day 
in the first week of life indicating rapid developments to postnatal contractile 
structures [129]. Numerous studies have shown that throughout the myocardial 
development, the E-C coupling mechanism can change dramatically [130-132]. 
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Wibo et al reported an increase of more than double in number of RyRs per gram 
of tissue between 2 and 30 days of age in conjunction with proliferation of the SR 
membranes [130]. In rat cell culture model, cardiomyocytes have been shown to 
have a different RyR cellular arrangement, density and Ca2+ transit. The major 
differences are between day 1 and day 4 [133].  However, since this has not been 
studied in vivo, one cannot confidently conclude its application to E-C coupling 
during development of an intact and working heart cell. 
 
In the first few weeks after birth, the SR and surface membrane systems are not 
yet fully developed. As a result the release and reuptake of Ca2+ in E-C coupling 
mechanisms in the neonate is less active. Neonatal SRs, however, have an intact 
Ca2+ store, indicating that the neonatal SR is primed with Ca2+ that is not fully 
released in response to a stimulus [134]. The T-tubular network continues to 
develop for weeks following birth and initiates to extend from the periphery to 
the interior of the cell, 7 days after birth [135].  
 
There is also a significant difference in action potentials of neonate and adult 
hearts [136]. Neonatal rats have longer action potential plateau duration with an 
increased delay prior to repolarisation when compared to adult rats [137]. Studies 
of developing human cardiomyocytes indicate that with age, L-type Ca2+ channels 
increase, whilst T-type Ca2+ channels decrease. These studies also showed that 
NCX mRNA and protein levels were higher in foetal hearts when compared to 
adult, whereas SERCA2a protein expression increased with age, with a maximal 
expression in adulthood [138, 139]. There is also a lower density with different 
inactivation of outward K+ channels in neonatal cardiomyocytes [136]. A 
significant reduction in action potential duration was observed between one day 
old and mature cardiomyocytes, which corresponded to a significant increase in 
K+ currents and the mRNA expression of the involved K+ channels [140]. 
 
Higher levels of T-type channels and NCX imply that; sarcolemmal Ca2+ handling 
proteins play a key role in the sarcolemmal Ca2+ entry via the abundant T-type 
channels (rather than few L-type channels) in neonatal hearts [138]. It is proposed 
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that structures such as SR and T-tubules along with Ca2+ handling proteins in 
immature human heart become equivalent to those of an adult at about three 
weeks of age [139]. 
 
Table 1 is a summary of some of the physiological differences between adult and 




Table 1  Physiological Difference Between Paediatric and Adult Myocardium and Potential Impact of 




Potential Impact on 
Ischaemia Tolerance in the 
Paediatric Heart 
Preferred substrate for adenosine 
triphosphate production 
Glucose Fatty acids Increase 
Glycogen content High Low Increase 
Insulin sensitivity Impaired Normal ? 
Calcium handling (intracellular) Impaired Normal ? 
Calcium sensitivity Increased Normal Decrease? 
Antioxidant defence Low High Decrease 
5′ nucleotidase Low High Increase 
Catecholamine sensitivity Low Normal ? 
Ischaemic preconditioning Absent Present ? 








1.6.3 Cardiac metabolism during hypoxia: 
 
Principally hypoxia or oxygen deficiency is defined as an imbalance between 
oxygen supply and demand. Heart energy is mainly provided in the form of 
adenosine triphosphate (ATP). As discussed above, most of this ATP production 
is via oxidative phosphorylation in the mitochondria. 
Hypoxia can lead to ionic changes in cardiomyocyte that can result in 
accumulation of H+; i.e. acidosis [105, 142]. 
 
Throughout hypoxia, there is a decline in ATP production that derives from 
mitochondrial oxidative phosphorylation. This is caused by a fall in carbohydrate 
and fatty acid oxidation. Cardiac metabolism thus switches to an anaerobic mode 
and induces the accumulation of pyruvate that is converted to lactate. Increase in 
intracellular lactate and protons instigates acidosis in the cardiomyocyte [142]. 
Proton increase also induces an intracellular increase of Na+ and Ca2+ through 
the Na+/H+ and Na+/Ca2+ exchangers [105]. Moreover, accumulation of 
intracellular proton can obstruct the activity of contractile proteins by 
competing with calcium [143, 144]. 
 
The mitochondria generate the vast majority of cellular energy production as 
ATP. This ATP synthesis is associated with reactive oxygen species (ROS) 
production. Energy production is mainly by oxidisation of glucose, pyruvate and 
NADH, which is oxygen dependent. During hypoxia, ATP availability becomes 
limited due to the build-up of non-esterified fatty acid levels, acidosis, and Krebs 
cycle blockade. Furthermore, hypoxia induces increased levels of mitochondrial 
NADH which can stimulate the augmentation of the NADH/NAD+ ratio [105]. In 
vivo studies have shown that myocardial mitochondria increase in number when 
chronic hypoxia is induced [145].  
 
There is evidence that with ischaemia-reperfusion, the myocardial metabolism 
can become disturbed, leading to the opening of mitochondrial permeability 
transition pore (mPTP) during this injury [146].The mitochondrial permeability 
transition pores (mPTP) are non-selective pores, permeable to very small 
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molecules (<1.5 kDa). They open in certain strict conditions such as abnormal 
elevation of calcium levels [146]. This opening of pores can lead to two major 
consequences. The first one is uncoupling, that may lead to ATP hydrolysis rather 
than synthesis. The second consequence is mitochondrial swelling [146]. Whether 
the ischaemia-reperfusion injury is reversible or irreversible, largely depends on 
the extent of the mPTP opening [147, 148]. All these imply that reactive oxygen 
species (ROS) production in cardiomyocytes is ultimately affected by hypoxia-
induced stress. 
 
ROS are highly reactive molecules that are present in all cells. They contain an 
unpaired outer shell of electron that makes them highly reactive. In 
cardiomyocyte, reactive oxygen species are thought to be vital for intracellular 
signalling during hypoxia [149]. Mitochondrion is the principle source of ROS and 
ROS are formed as by-products during the oxidative phosphorylation. 
The four main ROS are:  
 
peroxynitrite (·OONO-) hydrogen peroxide (H2O2) 
hydroxyl radical (·OH-)  
superoxide anion (·O2-) 
 
Peroxynitrite which is a result of superoxide and nitric oxide, is known to have a 
strong detrimental and toxic effect on the myocardium [150-152]. Via Fenton 
chemistry, hydrogen peroxide may be converted into hydroxyl radical. Once the 
hydroxyl radicals are formed, they can then react with the cell nucleic acids, 
lipids and proteins and cause cell damage and even death [153]. Hydroxyl radicals 
have lipid peroxidation characteristics, which is basically an oxidative 
degradation of lipids. This can affect the ion channels and pump function in 
cardiomyocytes and lead to contractile injury [153]. 
Superoxide anions can be produced in the electron transport chain and can then 
be converted into hydrogen peroxide by superoxide dismutase (SOD). Depending 
on the cellular positioning of SOD and their related metal cofactor, three different 
SOD isoforms exist [154]: 
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CuSOD (SOD1) which is intracellular 
MnSOD (SOD2) which is located in the mitochondria 
ZnSOD (SOD3) which is extracellular 
 
Although ROS is fundamentally produced by mitochondrion, there are other 
sources to ROS. These additional sources are primarily NADPH oxidase (NOX), 
nitric oxide synthase (NOS) and xanthine oxidase (XO). XO catalyses the oxidation 
of hypoxanthine to xanthine and then further to uric acid [155-158]. This oxidation 
process will lead to production of hydrogen peroxide and superoxide, which can 
then result in cell injury [159]. 
NOS are composed of three isoforms [160]. Of all three NOS isoforms, endothelial 
NOS (eNOS) is the one that as a result of limited bioavailability of 
tetrahydrobiopterin (BH4) can easily get uncoupled and ultimately lead to 
superoxide production [161].  
ROS, as well as being harmful to the cell, have been shown to have an important 
role in signalling. ROS are known to act as second messenger downstream of 
certain growth factor stimuli such as TGF or PDGF [162].  
 
Production of ROS and the mechanisms that could counterbalance their 
production is summarised in Figure 13. 
 
Figure 13 Simplified scheme of ROS production. 
O2.=Superoxide, ·OH=hydroxyl radical, ·OONO-=peroxynitrite, GPx=glutathione peroxide, NOS=nitric oxide 
synthase, NOX= NADPH oxidase, XO=xanthine oxidase, SOD=superoxide dismutase 
(Image reillustrated from Giordano 2005[153]) 
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A crucial element of the hypoxic response is the production of a transcription 
factor called hypoxia inducible factor 1 (HIF-1) and is the most important factor 
during a hypoxic state [163]. It is composed of a constitutively expressed β subunit 
(HIF-1β), and an inducible α subunit (HIF-1α) [163]. Throughout normoxic 
conditions, HIF-1α is a target for prolyl hydroxylation by HIF prolyl-hydroxylase, 
which utilises oxygen as a co-substrate. This results in HIF-1α degradation by an 
ubiquitin ligase and then destruction by the proteasome. However, in hypoxic 
circumstances, HIF prolyl-hydroxylase is inhibited and HIF-1α protein 
expression is therefore stabilised, which leads to HIF-1α accumulation in 
cytoplasm and ultimately in the nucleus [164].  
 
 
 Cardiomyocyte Kinases are also affected in hypoxic conditions. Several 
signalling pathway specific protein kinases are controlled during hpoxia. These 
protein kinases are; mitogen activated protein kinase, Phosphatidylinositol 3’-
kinase, Protein kinases C. 
 
 Mitogen activated protein kinases (MAPK):  
 
MAPK are serine/threonine-kinases. They play an important role in intracellular 
signalling. Some stimuli including hypoxia can activate MAPK in cardiomyocytes 
[165-169]. This has been demonstrated in cultured rat cardiomyocytes [170, 171]. 
 
 
 Phosphatidylinositol 3’-kinase (PI3K):  
 
PI3K can be activated by different stimuli such as receptor protein tyrosine 
kinases (RPTK) and heterotrimeric G-protein-coupled receptors (GPCR). PI3K 
catalyses the conversion of phosphatidylinositol 4,5-bisphosphate (PIP2) to 
phosphatidylinositol 3,4,5-tris-phosphate (PIP3). This leads to the activation of 3-
phosphoinositide dependent protein kinase-1 (PDK1), which in turn activates 
many proteins including protein kinase B (PKB) also known as Akt. Activation of 
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the PI3K/PDK1/Akt pathway is known to have a cytoprotective characteristic in 
all different cells [172]. 
A summary of the survival pathway mediated by the PI3K/PDK1/Akt axis is 
illustrated in Figure 14. 
 
Figure 14 Simplified scheme of the PI3K/PDK1/Akt pathway. 
(Reillustrated image from Katso 2001[172]) 
 
 
Protection of cardiomyocyte against hypoxic/ischaemic conditions via PI3K/Akt 
pathway has been demonstrated in various studies. This protection has been 
shown in vivo as well as in vitro [173-176]. Ravingerova demonstrated that in 
isolated rat heart, during ischaemia-reperfusion injury, there was an increase in 
the size of infarct when PI3K was pharmacologically inhibited. This indicates a 
possible role for PI3K in cell survival [174].  
There are also reports that heat shock protein 90 (HSP90) is associated with the 
survival pathway mediated by the PI3K / Akt axis [177]. In a separate study 
Wang et al demonstrated an increase in HSP90 levels in rat cardiomyocytes 







 Protein kinase C (PKC): 
  
PKC is also a family of serine/threonine-kinases. It plays a significant role in the 
signalling events associated with myocardial contractions [178]. PKC has 
numerous isoforms. These isoforms are classified into four categories: 
conventional (α, β and γ), novel (δ, ε, η and θ), atypical (ζ and λ) and lastly the 




1.6.3.1 Ischaemia-Reperfusion Insult and Vulnerability of the Developing 
Cardiomyocyte compared to adult: 
 
Although a general belief is that the normal neonatal myocardium is more 
resistant to ischaemia-reperfusion injury than mature adult myocardium [180, 181], 
this topic remains controversial and there are conflicting reports in the literature 
regarding this.  Doenst et al reported a greater neonatal myocardial ischaemia 
tolerance versus adult [141]. Additionally, there are other reports suggesting that 
in comparison to an adult cardimyocytes, the postnatal developing 
cardiomyocytes demonstrate a greater resistance against injurious effects of I/R 
[129, 137, 182-185]. Although there are some theories to explain this, the exact 
mechanism behind this remains unclear [185]. Some of these theories are: lower 
energy demand, higher tissue glycogen and glycolysis [186], greater anaerobic 
capacity and also variances in Ca2+ handling and ROS production in postnatal 
[185]. There appear to be strong associations between the superior postnatal 
resistance against detrimental effects of I/R and differences in the ROS 
generation and/or removal upon reperfusion [129, 184, 187]. This is supported by the 
findings of de Jong et al when they showed significantly higher levels of xanthine 
oxidoreductase in adult rat cardiomyocytes when compared to the new-born 
[127]. This implies that the lower activity of a younger heart may contribute to its 
greater resistance to ischaemia. 
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By contrast to the above studies, there are some reports indicating that the 
postnatally developing myocardium is more susceptible to reperfusion injury 
when compared to the adult heart [188-190].  
Wittnich et al. reported that adult pigs could tolerate 50% longer period of 
ischaemia before they developed hypercontracture when compared to the 
newborn pigs [191]. There are also reports that neonatal cardiomyocytes are more 
susceptible to Ca2+ overload [192]. Other reports have suggested that during 
ischaemia, neonatal heart accumulates more H+ with a lower capacity to buffer 
the intracellular pH [190]. Finally there are also some reports that in the clinical 
setting, the paediatric myocardium is more susceptible to ischaemic injury than 
adult during cardiac surgery [193]. 
 
More studies may need to be carried out on this topic to explain these conflicting 
results.  
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1.6.4 Response to stress, inflammation and myocardial damage 
 
 There are numerous studies that have investigated cardiac insults as a result of 
myocardial ischaemia-reperfusion injury.  The sudden oxygen supply to any organ 
including myocardium, which has been subjected to ischaemia/hypoxia, could lead to 
production of harmful components such as reactive oxygen species, hormones and 
cytokines [194, 195]. Re-oxygenation injury is therefore one of the adverse effects of 
treatments available for acute myocardial infarction. This is caused by restoration of 
blood flow through the coronary arteries in order to improve the survival of patients 
with cardiovascular diseases [196]. It also has been described that myocardial injury 
can be worsened if the reperfusion is associated with cardioplegic arrest [197].  
 
1.6.4.1 Stress response: 
 
Stress response can be defined as body’s reaction to a stressor, which can result in 
production of some inflammatory factors. In a clinical setting, cortisol is considered to 
be an important stress indicator [198, 199]. Stimuli such as infection, burn, pain, 
ischaemic-reperfusion injury, or even mental stress, can activate the hypothalamic-
pituitary-adrenal (HPA) axis. This can lead to the release of corticotropin releasing 
hormone (CRH). CRH can then trigger the release of adrenocorticotropic hormone 
(ACTH) by acting on the anterior part of the pituitary gland. ACTH in turn stimulates 
the adrenal cortex to release glucocorticoids such as cortisol [200]. Cortisol activates 
the hepatic gluconeogenesis process, which then lead to an increase in blood glucose 
level. Cortisol has also immunosuppressive and anti-inflammatory properties. By 
inhibiting genes that are involved in coding for several cytokines including IL-2, IL-6 
and IL-8, cortisol supresses cell mediated immunity [201]. In addition to this, cortisol 
diminishes eosinophilia as well as inhibiting many functions of leukocytes and 
immune accessory cells triggering anti-inflammatory response.  
There are suggestions that glucocorticoids have cardioprotective properties [202, 203]. 
Barzilai et al. demonstrated a reduction in mortality rate following acute myocardial 
infarction in patients who were treated with hydrocortisone [202]. In a separate study, 
Valen et al. showed in a rat experimental model that glucocorticoid can have 
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cardioprotective properties [203]. There are reports that in adult patients who 




Inflammation is part of the body’s protective reactive complex response to a noxious 
stimulus with the intention to eliminate the initial cause of cell injury as well as the 
necrotic cells and tissues resulting from the original insult [41]. Many studies have been 
carried out in inflammatory response in cardiovascular diseases which  involve 
molecular interactions between cardiomyocytes, endothelial cells and leukocytes  [204]. 
Normally, vascular endothelial cells oppose bonding to leukocytes, yet in certain 
conditions such as atherosclerosis this physiology is disturbed. The adhesion of 
leukocytes to the endothelial wall leads to increased expression of inflammatory 
mediators such as cytokines [204]. Cytokines are important components of the 
inflammatory response. Cytokines can be subdivided to pro-inflammatory and anti-
inflammatory. The pro-inflammatory cytokines promote inflammation, whereas anti-
inflammatory cytokines suppress the activity of pro-inflammatory cytokines resulting 
in inflammation reduction [205].  
It is a well-known fact that cardiac surgery with the aid of cardiopulmonary bypass 
(CPB) is associated with a higher acute inflammatory response. This may affect the 
myocardial function and post-operative recovery [206]. In the heart, interleukin 6 and 8 
(IL-6 and IL-8) play a pro-inflammatory role while IL-10 is described to have an anti-
inflammatory effect [206]. IL-10 has also been described to be cardioprotective in the 
context of myocardial ischaemia-reperfusion injury in mice [207]. Injured myocardium 
can be a source of pro-inflammatory cytokines such as tumour necrosis factor α (TNF 
α) and IL-6. [208]. Moreover, ischaemic treatment has been shown to induce IL-6 
production in adult cardiomyocytes [209]. IL-8 is another pro-inflammatory cytokine 
and has also shown to be released by the ischaemic myocardium. IL-8 can have a 
critical role in neutrophils recruitment [210]. 
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1.6.4.3 Myocardial Injury: 
 
Myocardial injury is damage to the heart tissue, which could lead to myocardial 
dysfunction and can occur after ischaemia-reperfusion. Reperfusing the myocardial 
tissue following a period of ischaemia can lead to myocardial cell necrosis [196]. 
Moreover, it is believed that during the reperfusion of ischaemic myocardium, ion 
homeostasis is lost through calcium sequestration in the cells with disturbances in the 
Na+/K+ and Na+/Ca2+ pumps. Reoxygenation may result in accumulation of 
intracellular hydrogen ion causing acidosis, which can be lethal for the cells. Acidosis 
can also prevent the contractile apparatus to function normally and can lead to 
cardiac failure [196]. Myocardial injury may be diagnosed by raised levels of serum 
troponin which is normally located inside cardiomyocytes [211]. Troponin has three 
components: C, I and T. They are integral to the function of striated muscles and exist 
as a complex with actin and tropomyosin on the thin filament of the contractile 
apparatus [212]. Troponin-C binds calcium and regulates the activation of thin 
filaments during contraction. Cardiac troponin-I is an inhibitory component of 
contractile interaction and troponin-T binds to tropomyosin [212]. Although both 
cardiac troponin T and I are used in clinical settings to assess myocardial injury, there 
are some evidences indicating that cardiac troponin-I is a more sensitive and specific 
marker for assessment of myocardial injury. It is also argued that the levels of 





1.7 Cardiopulmonary Bypass 
 
It is over 60 years since John Heysham Gibbon for the first time performed a 
successful open-heart surgery using the heart-lung bypass machine. 
On 6th of May 1953 in Philadelphia, J.H. Gibbon, Jr, MD, of the Jefferson University 
Medical Centre, closed a large secundum atrial septal defect in an 18-year-old lady 
with the aid of cardiopulmonary bypass (CPB)[215]. Cardiopulmonary bypass and open 
heart surgery has since majorly developed.  
 
It may not be possible to perform cardiac surgery without having to stop the heart and 
bypassing the pulmonary circulation. Cardiopulmonary bypass machine, featuring a 
pump to act as a substitute for the function of the heart and a gas exchange device, the 
“oxygenator,” to act as an artificial lung can facilitate this. This will allow to transiently 
ceasing the circulation to the patients’ heart and lung and to suspend respiratory and 
cardiac activity, providing a safe and controlled environment for cardiac surgery.      
 
The basic mechanism of the CPB machine is as follows: Venous blood is drained from 
the right atrium or large veins through a plastic cannula into the reservoir. From there 
it is pumped through the oxygenator back into the patients’ arterial system through a 
different plastic cannula that inserts into either aorta or another large artery. As the 
blood transitions through the oxygenator, the partial pressure of carbon dioxide is 







Figure 15 Typical configuration of a cardiopulmonary bypass circuit. 




Since the application of extracorporeal circulation and CPB, the term oxygenator has 
been used, however blood gas exchange device is a more correct description. This is 
because its function is to regulate oxygen, carbon dioxide and nitrogen. It also 
facilitates the administration of anaesthetic gases during CPB. 
 
Some oxygenators are designed to have special coating or treatments that reduce the 
biochemical cascades affiliated with systemic inflammatory response (SIR). This is 
aimed to minimise CPB-induced SIRs [217-220]. The other important considerations in 
oxygenator design include flow related characteristics, aiming to decrease blood cell 
trauma as well as minimising the priming volume and device surface area. The heat 
exchanger of the oxygenator must also be able to proficiently transfer heat energy and 
efficiently thermoregulate.  
 
The mechanisms of gas exchange between the native lung and oxygenator are 
different. In the lungs, red blood cells pass through pulmonary capillaries in single file, 
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reducing the distance for O2 diffusion. Therefore except in the case of extreme 
exercise or severe lung disease, the rate of oxygen transfer is not limited by 
diffusion[24]. In the oxygenator however, since the distances are much greater, to 
achieve an adequate gas transfer, it requires a significant difference in partial 
pressures of gases to exists between the gas and blood phases of oxygenators, even 
under normal operating conditions [221]. 
 




By using gas blenders, oxygenators can ventilate with different percentages of O2 (21-
100%). Gas blender allows blending medical grade air and oxygen, to maximise the 
driving pressure difference for O2 diffusion [221].  
 
1.7.2 Myocardial Protection and Cardioplegia Delivering System: 
 
A major priority during cardiac surgery is myocardial protection during the ischaemic 
period. This can be achieved by using a solution referred to as “cardioplegia” that 
induces a state of hibernation of the heart.  
The term myocardial protection indicates the possibility of myocardial injury of some 
sort. In cardiac surgery this is largely exhibited by injury as a result of ischaemia-
reperfusion [221]. However, one must not forget that myocardial protection does not 
exist in isolation; and it is important to consider non-cardiac organ protection as well.  
Myocardial Injuries as a result of ischaemia-reperfusion can be classified into two 
separate categories, reversible and irreversible. Myocardial oedema and a temporary 
decline in cardiac function are the manifestation of reversible myocardial injuries that 
resolve with time without significant long-term sequelae. Conversely, irreversible 
myocardial injuries implicate myocardial apoptosis or necrosis that can lead to 
release of some cardiac biomarkers such as creatine phosphokinase (CK) or troponin 
(Tn) into the circulation as well as electrocardiographic changes. Irreversible injuries 
result in permanent abnormalities of cardiac function [221]. 
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During the early days of cardiac surgery, there were reports of successful surgery 
when the heart was arrested for a very short period [222-226]. However as the cardiac 
surgery advanced, more complex cardiac cases were considered for surgery, which 
required a longer period of cardiac arrest. This extended phase of unprotected cardiac 
ischaemia resulted in greater myocardial injury and poor outcomes. Later 
hypothermia was considered as a measure to allow a lengthier period of safe cardiac 
arrest. However it became apparent that after an extended period of time, despite 
hypothermia, the myocardium is subject to injury and quite often resulted in “stone 
heart” [221].  
 
In 1955 and 1957, Melrose induced cardiac arrest by using potassium citrate. 
Although somewhat primitive (a 0.5% solution of potassium citrate was injected 
directly into the aortic root after a cross-clamp had been applied), it did effectively 
stop the heart [227]. Unfortunately, the Melrose solution in isolation did not provide 
adequate myocardial protection, and its popularity weakened.  
 
The extensive work of Hearse and Braimbridge et al at St. Thomas’ Hospital in London 
on cardioplegia solution ultimately led to the developed the “St. Thomas Solution 1 
(STH 1)” which provided reliable cardiac arrest with good myocardial protection  [228, 
229]. Their solution was a major advancement in the field of myocardial protection and 
gained a substantial international popularity. In the late 1970s Follett and Buckberg 
described more complex strategies of cardioplegia delivery, including refinements in 
temperature and route, which further advanced the efficacy of cardioplegia [230, 231].  
 
Currently, countless choices can be considered when choosing a myocardial 
protection strategy and there are more than 150 different available cardioplegia 
solutions [232] . The primary differences in composition of cardioplegia solutions aim 




Although cardioplegic arrest has become the mainstay of myocardial protection, the 
utility of intermittent fibrillation and deep hypothermic circulatory arrest, also needs 
to be appreciated.  
 
Cardioplegia can be delivered in many different ways; antegrade, retrograde, or both 
either intermittent or continuous.  
It is important to bear in mind that, there is no such thing as “best” cardioplegia 
strategy for all circumstances and practice environments; however, a working 
knowledge of the range of cardioplegia options that are available is useful so that the 
surgeon can provide optimal clinical care. 
 
1.7.2.1 Cardioplegia Composition: 
 
Cardioplegia is a solution that utilises a rapid cardiac arrest in diastole and provides 
myocardial protection from ischaemia and reperfusion. Potassium with 
concentrations ranging from 10 to 40mmol/L is the most commonly utilised agent to 
deliver cardiac arrest [228, 230, 231, 238].  
Cardioplegia composition has been described as either “intracellular” (low sodium 
and calcium concentrations) or “extracellular” (higher concentrations of sodium, 
calcium, and the addition of magnesium)[221].  
Furthermore, cardioplegia can be divided into two subtypes; crystalloid cardioplegia 
and blood cardioplegia. A variety of supplementary electrolyte and pharmacologic 
mediators with different concentrations can be added to each of these subtypes.  
1.7.2.2 Temperature and myocardial protection: 
 
Despite numerous cardioplegia solutions there are disagreements on the type of 
cardioplegia that should be used despite attempts by many studies to address this 
issue [12, 239-243]. Additionally, there is no unified consensus in the literature regarding 
different cardioplegia temperatures and their myocardial protection efficacy [244, 245]. 
Although some studies have demonstrated the superiority of one cardioplegia 
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temperature over another [246, 247], other studies have been unable to demonstrate a 
difference [248, 249].  
 
One possible reason to these conflicting conclusions may be the fact that, different 
patients may benefit from different cardioplegia regimen. Given the variation in 
cardioplegia composition, temperature, duration and delivery routes in different 
studies, makes comparison and conclusions very difficult and problematic. 
In our institution, Ascione et al. evaluated the differences in myocardial protection 
afforded by warm and cold intermittent antegrade blood cardioplegia in patients with 
hypertrophic hearts undergoing aortic valve surgery [250]. Authors reported less 
myocardial injury and less ischaemic stress in patients receiving cold cardioplegia. 
Caputo et al. also from our institution, demonstrated no difference in post-operative 
renal impairment between the cold and warm cardioplegia in paediatric cases 
undergoing cardiac surgery [251]. Fan et al. in a meta-analysis of 41 randomised 
controlled trials, which included 5879 patients, reported that comparison between 
warm and cold cardioplegia for myocardial protection during cardiac surgery resulted 
in, similar incidences of clinical events, significant improvement in postoperative 
cardiac index and reduction in postoperative enzyme release [244].  
 
1.7.2.3 Myocardial Protection and Preservation for Neonates and Infants: 
 
It is important to appreciate that cardiac surgery on the neonate and infant heart 
differs from cardiac surgery on the adult heart in a number of ways. The coronary 
arteries and myocardium are, for the most part, normal in patients with congenital 
heart disease. This can provide a uniform delivery of cardioplegia. However, the 
surgeon is faced with a heart that could be in different phases of development. This 
matter is of significant importance to the surgeon since during various stages of 
myocardial maturity, some transitions take place that influence the ability of the 
myocardium to withstand periods of ischaemia and injury.   The transitional point is 
not exactly known but it is thought to occur in the first year of life or possibly within 
the first 3 months of life [221]. 
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Some believe that the normal neonatal myocardium is more resistant to ischaemia-
reperfusion injury than mature adult myocardium [180, 181]. However, this added 
resistance does not seem to be present in the hearts of cyanotic neonates and children 
[5, 252]. Therefore myocardial protection techniques must be tailored with respect to 
the age of the patient, pathology and complexity of the procedure to ensure the best 
outcomes.  
 
1.7.2.4 Cardioplegia and hypothermia in neonates and infants: 
 
There are disagreements over optimal strategy for myocardial protection in the 
neonate and infant [253]. However, the most frequently practiced principles to protect 
myocardium during paediatric cardiac surgery are; hypothermia to minimise 
myocardial metabolic activity and delivery of cardioplegia to temporarily cease the 
cardiac contractile and electrical activity [221].  
Primarily, administration of cardioplegia is for cessation of all contractile and 
electrical activity of the heart that results in a significant reduction of energy 
consumption, even at normothermia [254].  
In neonates and infants, hypothermia alone may provide a significant amount of 
myocardial protection. In fact some authors have suggested that in certain conditions, 
cardioplegia may not even be necessary [141, 255]. This theory is supported by reports 
suggesting equal or superior myocardial protection with hypothermia alone when 
compared to hypothermia combined with cardioplegia [256-259]. It is noteworthy 
however to point out that these studies were carried out in very low systemic 
temperatures (15°C or less). Reports from other studies at a higher temperature 
steadily show that hypothermia with the addition of cardioplegia is advantageous [12, 
260, 261]. 
 
Figure 16 [141] plots benefit from cardioplegia against the non-cardioplegic 
establishment of the same temperature (i.e., topical cooling, blood perfusion etc.) for 
myocardial function during ischaemia. This chart indicates that the benefit of 




Figure 16 Benefit of cardioplegia over establishment of the same 
temperature by a non-cardioplegic method (i.e., topical cooling, blood 
perfusion, perfusion with crystalloid buffer) as a function of myocardial 
temperature during ischaemia. A positive value indicates that 
cardioplegia was better than the non-cardioplegic method. A negative 
value indicates that the non-cardioplegic method was better. (Doenst T, 
Schlensak C, Beyersdorf F. Cardioplegia in paediatric cardiac surgery: do 











Excessive fluid accumulation is a phenomenon that often neonates and infants 
encounter through exposure to CPB [262-264]. This oedema develops not only in the 
periphery but also in vital organs such as the brain, heart, intestine, and lungs [265]. 
Different methods can be used to remove or minimise this excess fluid in order to 
increase the haematocrit levels to satisfy oxygen demands. Utilisation of 
ultrafiltration, which removes excess fluid while still on CPB, is one of the ways to 
achieve this. However, this can be very challenging in neonates. In this group of 
patients the circuit is very small and as a result any removed fluid may have to be 
replaced again to maintain adequate reservoir level. Therefore zero-balance 
ultrafiltration (Z-BUF) during CPB may be a more practical method of fluid removal. In 
this method, volume of fluid exchange corresponds to the volume filtered. Studies 
have shown, Z-BUF to be beneficial as it can reduce postoperative blood loss, decrease 
time to extubation, and remove considerable amount of circulating TNF, IL-10, 
myeloperoxidase, and C3a [266, 267]. Modified Ultrafiltration (MUF), which was 
described by Elliott and Naik is another form of ultrafiltration that is performed after 
the completion of CPB while the aortic and venous cannulae are still in place. This 
appears to be a more effective form of ultrafiltration [268, 269]. MUF has the advantage 
of filtering the patient's extracellular blood volume as well as the residual circuit 
volume, which results in greater haemoconcentration [268]. Both conventional and 
MUF are effective in filtering inflammatory mediators from the circulation [270]. 
However, MUF has been shown to be more effective in haemoconcentration and 
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improving both, pulmonary compliance, and ventricular functional recovery [268, 271, 
272].  
 
1.7.4 Prime volume: 
 
Prime volume is the amount of fluid necessary to fill both arterial and venous limbs of 
a cardiopulmonary bypass circuit. Prime volume also includes the fluid required for 
the reserve volume in the venous reservoir that prevents air entry to the arterial 
segment of the circuit. 
 
In adults, the prime volume is about 30-35% of patients’ total circulatory volume. 
However, in children, particularly neonates and infant, even the smallest possible 
priming volume exceeds patients total blood volume. Therefore, using non-blood 
prime solutions in these cases is not a feasible option.  
 
Principally, an ideal priming solution must have a similar pH, tonicity and electrolyte 
arrangement to the patients’ plasma. Tonicity is the most important matching 
characteristic for the priming volume since a tonal mismatch will result in red cell 
breakdown (haemolysis) leading to fluid shifting from extracellular to the 
intracellular compartment. This fluid shift is observed with hypotonic solutions and 
may occur in any tissue or organ, but those organs that are particularly susceptible to 
this fluid shift are the brain and lungs [273].  
 
 
Despite variation in practice amongst different units in the United Kingdom, the most 
frequently used crystalloid to prime cardiopulmonary bypass circuit is the 






1.7.5 Effects of pH and temperature on oxygen delivery: 
 
Blood is predominantly composed of plasma and red blood cells (RBCs). The fractional 
volume of the blood composed of RBCs, is referred to as ‘haematocrit’. Blood carries 
oxygen in two forms:  
1. Dissolved in plasma and RBC water (~ 2% of the total) 
2. Reversibly bound to haemoglobin (~ 98% of the total) 
 
At a physiological PO2 (~100 mm Hg), only a small amount of oxygen is dissolved in 
the plasma since oxygen has a low solubility. However the physically dissolved form of 
oxygen becomes substantial once the PO2 is raised. 
 
Blood pH as well as body temperature can affect oxygen-carrying capacity and 
delivery.  
 
An increase in blood carbon dioxide results in decreased pH (acidosis), which reduces 
the affinity of haemoglobin for oxygen. The oxygen dissociates from the Hb molecule, 
shifting the oxygen dissociation curve to the right. Therefore, more oxygen is needed 
to reach the same haemoglobin saturation level as when the pH was higher. A similar 
shift in the curve also results from an increase in body temperature. Temperature is 
associated with both the delivery and consumption of oxygen and is therefore vital to 
effective CPB. A drop of 10°C in temperature slows the rate of metabolic reactions by 
about half. In addition hypothermia increases blood viscosity and shifts the oxygen-
haemoglobin dissociation curve to the left, both of which decrease oxygen 
delivery/release. As blood temperature falls, gas solubility rises and the partial 
pressure of carbon dioxide decreases (PCO2 decreases 4.4% for every °C drop in 
temperature) resulting in alkalosis. 
1.7.6 Acceptable haemodilution: 
 
Some degree of haemodilution may be beneficial as blood viscosity is reduced, 
improving microcirculatory flow [274]. In general, acceptance of a degree of 
haemodilution during CPB, the use of autologous priming, collection and processing of 
shed mediastinal blood and the return of residual pump blood at the end of CPB can 
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all lead to a decrease in allogenic blood transfusions with their consequent risks and 
uncertain risk/benefit profile [275, 276]. 
 
HCT is the main determinant of the oxygen-carrying capacity of blood.  
Factors affecting the HCT during CPB include [273]:  
• Patient size; 
• Preoperative haemoglobin concentration/HCT;  
• Pre-CPB blood loss;  
• Pre-CPB fluid administration;  
• CPB prime volume; and 
• Urine output  
 
Theoretically, minimum acceptable HCT should meet the oxygen delivery (DO2) 
required to match systemic O2 consumption (VO2). However, DO2 is not controlled by 
reflex mechanisms, but by the perfusionist. During CPB whole body DO2 is a function 
of pump flow and arterial oxygen content, the latter being primarily determined by 
the HCT. The major determinants of VO2 are temperature and level of anaesthesia. 
 
Oxygen consumption (VO2) can be calculated using the Fick equation: 
 
VO2= Q(C (a-v)) O2 
 
VO2  =  minute oxygen consumption (ml/minute) 
Q   =  cardiac output (l/minute) 
(C (a-v)) O2 = 1.34×Hb+P(a-v)02 
 
where 1.34 is the haemoglobin oxygen content at 100% saturation (ml/g), Hb is the 
haemoglobin concentration (g/l) and P(a-v)O2 is the arterio-venous oxygen partial 
pressure difference (mmHg). 
 
Indices of adequate total perfusion include pH, lactate and SvO2 (haemoglobin oxygen 
saturation in venous blood). A low SvO2 during CPB indicates an imbalance between 
DO2 and VO2 and requires a change in perfusion conditions. The SvO2 value should 
always also be interpreted in the context of core temperature. The solubility and 
haemoglobin binding affinity of oxygen increases with hypothermia, whilst organ 
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metabolic demand decreases, resulting in increased SvO2 if perfusion is adequate. 
 
1.7.7 Triggers of CPB induced organ damage: 
 
The key mechanisms in causing organ damage associated with CPB are [273]: 
 
 The activation of a systemic inflammatory response (SIRS), which is an 
inevitable consequence of CPB 
 
 Hemodilution and reduced blood viscosity, mainly at the onset of CPB, 
resulting in alterations in the distribution of blood flow to organs and 
flow characteristics of blood through capillary networks 
 
 
 Ischaemia/reperfusion injury to heart, lungs and organs supplied by 
the splanchnic circulation 
 
 Laminar rather than pulsatile flow, although the significance of this 
remains controversial. 
 
1.7.7.1 Ischaemia–reperfusion injury (IRI): 
 
IRI is the term used to describe the cellular injury that occurs on resumption of 
normal perfusion to an organ after a period of relative or complete ischaemia. This 
has already been discussed earlier, but in summary; during the ischemic period 
intracellular calcium accumulates due to the failure of ATP-dependent cellular pumps. 
On reperfusion, intracellular calcium levels further increase secondary to oxidative 
dysfunction of sarcolemma membranes. This cellular and mitochondrial calcium 
overload ultimately induces cardiomyocyte death by hypercontracture and opening of 
the mitochondrial permeability transition pores (mPTP) on the inner mitochondrial 
membrane. Opening of the mitochondrial PTP channels during early reperfusion (they 
remain closed during the ischemic period) inhibits the mitochondrial membrane 
potential, uncoupling oxidative phosphorylation, which being essential for ATP 
production, results in ATP depletion and cell death. Large quantities of oxygen free 
radicals are generated on reperfusion of ischaemic tissue. The oxygen free radicals, if 
present in sufficient concentration, overwhelm endogenous scavenging mechanisms 
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and cause further intracellular injury. Oxygen free radicals also exacerbate 
arachidonic acid metabolism and the production of leukotrienes and thromboxanes, 
promoting aggregation, transmigration and activation of neutrophils to further 
compound the injury. Neutrophils are the key final mediators of IRI by the production 
of toxic chemicals generated during the metabolism of oxygen and by the secretion of 
proteolytic enzymes released from granules stored in their cytoplasm. 
The rapid breakdown of ATP during ischaemia results in generation and accumulation 
of the metabolite hypoxanthine. The enzyme xanthine dehydrogenase normally 
metabolises hypoxanthine. Under conditions of ischaemia followed by rapid 
reperfusuion, xanthine dehydrogenase is converted to xanthine oxidase as a result of 
the higher availability of oxygen. This oxidation results in molecular oxygen being 
converted into highly reactive superoxide and hydroxyl radicals. Excessive nitric 
oxide produced during reperfusion reacts with superoxide to produce the potent free 
radical peroxynitrite. These radicals attack cell membrane lipids, proteins and DNA, 
causing further cell damage or death. 
 
1.7.8 Hyperoxic CPB, it’s pitfalls and the concept of normoxic CPB 
 
Despite the routine use of hyperoxic CPB in many cardiac centres throughout the 
world, this practise is probably unnecessary, since a PaO2 of 400–500 mmHg results in 
only a trivial increase of the oxygen content compared with a PaO2 of 100–150 mmHg 
[277].  
 
Usually CPB is commenced at a PaO2 in the range of 300–400 mmHg in cyanotic 
population undergoing corrective cardiac surgery. This can have a cytotoxic effect as a 
result of exposure to a high partial pressure of oxygen. In addition there are reports 
that hyperoxic CPB, can impair glucose regulation which can result in hyperglycaemia 
[278], diminish peripheral perfusion and skeletal muscle oxygenation [277]. 
 
One of the proposed strategies to minimise reoxygenation injury is the reduction of 
PaO2 during CPB. Studies have shown a direct correlation between the partial 
pressure of oxygen (PaO2) and reoxygenation injury [10, 254, 279], which can be avoided 
by controlling the PaO2 to the normoxaemic range (80–100 mmHg) during CPB [10, 279]. 
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In 1995, Buckberg et al [254] proposed the concept of ‘‘surgical reoxygenation injury of 
cyanotic myocardium’’. They reported that unintended rapid reoxygenation of 
cyanotic cardiomyocyte during a routine CPB may result in an oxygen radical-
mediated myocardial injury highlighting post-CPB cardiac dysfunction. Del Nido and 
co-workers in a clinical setting demonstrated the relevance of such myocardial injury 
by detecting increased lipid peroxidation in pre-ischaemic myocardial biopsies taken 
from the right ventricle of children with tetralogy of Fallot, showing oxidative injury at 
the start of CPB [8]. 
 
 
Morita and colleagues in two separate studies using animal models of acute 
hypoxaemia confirmed the role of reoxygenation injury in post-CPB myocardial 
dysfunction and addressed the significance of controlling PaO2 at the initiation of CPB 
for cyanotic hearts [18]. They also later confirmed that a period as short as 5 minutes of 
uncontrolled reoxygenation was enough to cause myocardial damage by establishing 
that controlling the PaO2 during blood cardioplegia from 5 min after the initiation of 
CPB had no protective effect on the myocardium [279]. 
 
 
The first clinical evidence of reoxygenation injury was reported by Allen et al followed 
by [14] Bulutcu et al [280]. They reported a significant depletion of the antioxidant 
reserve capacity in cyanotic infants following sudden reoxygenation with hyperoxic 
CPB. Allen et al. showed that this hyperoxic injury could be significantly minimised by 
utilising a lower PaO2 (FiO2 of 0.21) at the onset of CPB [14]. Although however, they 
pointed out that an FiO2 of 0.21 can still results in a PaO2 of 140–155 mmHg, which is 
substantially higher than the PaO2 of 80–100 mmHg. Similarly, Bulutcu et al.  
demonstrated that antioxidant depletion induced by reoxygenation can be 
significantly ameliorated by initiating CPB using FiO2 of 0.21 (PaO2, 90–110 mmHg)  
[280].  These clinical reports indicate the need to assess oxygenation status by PaO2 and 
not FiO2, in order to reliably achieve normoxia. By delivering nitrogen to the 
oxygenator it is possible to achieve a PaO2 of 80–100 mmHg in the CPB priming fluid 
with FiO2 of 21%. [281].  
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The first real clinical evidence of myocardial reoxygenation injury as a distinct entity 
from ischemia/reperfusion injury was reported by Modi et al. [5]. They studied twenty-
nine paediatric patients undergoing cardiac surgery. Twenty were cyanotic and 9 
were acyanotic. All patients underwent at least 30 minutes of hyperoxic CPB before 
ischemic cardioplegic arrest. They assessed troponin I at 1, 10, and 30 minutes of CPB. 
They reported an increase in troponin I levels with time in both groups however the 
rate of increase was greater in cyanotic population by about 3 times. 
 
It is important however to point out that higher oxygen levels during CPB should be 
considered if there is a requirement for a period of low flow or deep hypothermic 















2 - Method and Study Design
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2.1 Hypothesis and study proposal: 
 
Based on the earlier work of Modi et al. [5](discussed in the previous chapter), we 
hypothesised that by reducing the oxygen tension to the patient’s own levels 
(normoxic) on initiating cardiopulmonary bypass, we may attenuate the detrimental 
effects of cardiopulmonary bypass on myocardial function, and re-oxygenation injury.  
We proposed to carry out, in a prospective randomised clinical study, a comparison 
between normoxic (70-100 mmHg) and standard (relatively hyperoxic) (150-200 




Cyanosis was defined as a pre-operative diagnosis of a cyanotic cardiac condition plus 
oxygen saturation of 90% or less at all times. “Normoxia” referred to a pump prime, 
the pO2 of which is matched to the pO2 of the patient (i.e., normoxic for the patient). 
“Hyperoxia” referred to a pump prime prepared to the current “best practice” 
protocol, which has a pO2 relatively hyperoxic for a cyanotic patient.  
 
2.2 Method: 
Parents/guardians of cyanotic patients who were undergoing surgical repair of their 
congenital cyanotic heart disease that were suitable for this study were approached 
and an informed consent was abtained.  They were asked to sign a consent form, 
which was approved by Ethical Committee. The patients were then randomly 
allocated to either normoxic (70-100 mmHg) or standard (relatively hyperoxic) (150-
200 mmHg) CPB. Randomisation was accomplished by card allocation on the night 
before the surgery. The surgical team, except for the perfusionists, were blind to the 




Figure 17 Summary of study design 
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 Seventy-nine cyanotic patients undergoing corrective cardiac surgery between 
January 2003 and March 2007 at the Bristol Royal Hospital for Children were 
randomised to receive either controlled normoxic (70-100 mm Hg) or hyperoxic 
(150–200 mm Hg) CPB. All patients were in a stable condition without preoperative 
respiratory or inotropic support. 
 
Treatment allocations, stratified by age (<6 months vs ≥6 months), were generated by 
computer in advance of starting the study, using block randomisation with varying 
block sizes. Allocation details were concealed in sequentially numbered, opaque 
sealed envelopes. After consent was obtained the night before the operation, a patient 
was randomly assigned from the next numbered envelope.  
After the operation, all patients were admitted to the Paediatric Intensive Care Unit 
(PICU) and were managed according to unit protocols [283, 284] by intensivists and 
paediatric cardiologists who were also blinded to the treatment allocation. 
 
2.2.1 Anaesthetic and surgical techniques: 
 
All operations were performed using CPB with ascending aortic cannulation and 
bicaval venous cannulation. Anaesthetic techniques were standardised for all patients 
and followed the Check List: 
Induction: The normoxic group induction of anaesthesia was started with a 
fraction inspired oxygen (FiO2) of 0.21 and in the hyperoxic group with an FiO2 of 
0.50. Continuous pulse oximetry was used in every patient from the start of 
anaesthesia. 
Sevofluorane or midazolam (200 to 500 mcg/kg); pancuronium 200mcg/kg iv; 
fentanyl 5 mcg/kg iv; commence fentanyl infusion – 25 mcg/kg/hr; dexamethasone 
0.5 mg/kg iv (maximum 8mg); run isofluorane as required; reduce fentanyl infusion 
to 10 mcg/kg/hr after 1 hour. 
Pump drugs:  
Midazolam 500 mcg/kg; pancuronium 200 mcg/kg.  
Pre-CPB:  
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Fentanyl infusion as above; reduced to 10 mcg/kg/hr after 1 hour bypass. Fentanyl 
infusion increased to 15 mcg/kg/hr 
Post-CPB:  
Morphine/fentanyl infusion; midazolam +/- vecuronium until ready for extubation; 
phenoxybenzamine or SNP if necessary. 
2.2.2 Cardiopulmonary bypass (CPB) Techniques: 
Normoxic (Iso-oxic) CPB for the normoxic group: As discussed earlier, currently, the 
common practice is to deliver to the cyanotic patients, the same levels of oxygen that 
one would deliver to the acyanotic ones[1, 2, 8]. We have developed a novel and 
simple cardiopulmonary bypass strategy of controlled oxygenation at the Bristol 
Royal Hospital for Children[3] with a hypothesis that this could reduce the risk of 
ischaemic-reperfusion injury.  For this purpose, the CPB circuit is set up and primed 
usually with a homologous red blood cell/albumin prime or a clear prime, depending 
on the patient’s haemoglobin level. Just before the initiation of CPB, medical nitrogen 
is delivered to the gas exchange device (oxygenator) via a bacteriologic filter (0.2 μm) 
at a rate of between 100 and 200 mL/min while the prime is circulated at 
approximately 1000 mL/min. An in-line pO2 monitor measures’ the pO2 of the prime 
(in air this will equilibrate at roughly 150 mm Hg). Using this technique, we are able to 
reduce the pO2 of the prime fluid to less than 100 mmHg and actually match that of 
the patient’s own arterial pO2 levels. Before the establishment of CPB, the prime pO2 is 
confirmed using a point of care blood gas analyser, and the in-line pO2 monitor is 
calibrated. CPB is initiated in an “iso-oxic” manner and the pO2 levels of the 
arterialised blood are adjusted accordingly throughout the CPB. So by using air and 
minimum required O2 we maintain a SaO2 at preoperative levels as much as possible 
(SaO2<90%). Hence we just use an initial N2 flush and then we started CPB in air (FiO2: 
0.21), which keeps the pO2 at preoperative levels. We then slowly raise the pO2 so that 
termination of CPB occurs with an arterial pO2 of between 100 and 110 mm Hg. 
 




Cold blood (4-6o C) St Thomas’ I based cardioplegic solution (4:1 dilution of 
homologous or autologous blood/St Thomas’ I crystalloid cardioplegia) were used for 
myocardial preservation following aortic cross clamping in both groups, with the 
following composition (mmol/L): 16MgCl2, 2CaCl2, 20KCl, 147NaCl, 1.0 procaine HCl. 





2.2.3 Sample Size and Statistical Analysis: 
The sample size was calculated on the basis of previous similar studies carried out at 
our institution in which statistically significant reductions in troponin-I release (effect 
size 0.48) and in 8-isoprostane (effect size 0.94) were found with 55 and 42 patients, 
respectively[283]. With one preoperative and five postoperative measurements, a 
sample size of 40 per group has more than 90% power to detect effect sizes of 0.5 or 
more for both markers at the 5% level of statistical significance (2-tailed) assuming a 
correlation of 0.7 between preoperative and postoperative values and between 
postoperative measures. 
 
Continuous outcomes are summarised as an arithmetic mean and standard deviation 
if normally distributed or as a geometric mean or median and interquartile range if 
skewed. Categorical data are presented as actual counts and percentages.  
 
Skewed measures were log-transformed to achieve normality and the results were 
back transformed to the original scale.  
 
Biochemical markers measured at multiple time points were analysed with a mixed 
regression model. All the markers had skewed distributions and were analysed on the 
logarithmic scale.  
 
An overall estimate, pooled over all time points, is reported. Effect sizes (also known 
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as ‘strength of ssosiation’), which indicate the relative magnitude of the differences 
between means, are reported as mean differences (if normally distributed) or as 
ratios of geometric means (if skewed) with corresponding 95% confidence intervals 
(CIs) and p values. According to Cohen’s guidelines, an effect size of 0.2 or less is 
considered small and above 0.8 is large. Effect sizes between small and large are 
considered medium. 
 
The baseline results are not reported in the charts since this study was designed to 
assess the effect of normoxic versus hyperoxic CPB. However baselines blood samples 
were taken to make sure that there were no diffences between the two groups pre-
treatment.  
 
Since only scores of differences betwen two groups (normoxic and hyeroxic) were 




2.2.4 Data Collection: 
 
The collection of data included: clinical information (i.e. age, sex, body surface area, 
preoperative medications); pre and postoperative echocardiographic findings; 
preoperative oxygen saturation, routine pre- and postoperative blood tests (i.e. 
haematocrit, creatinine and electrolytes); operative procedural information (i.e. type 
of operation, CPB and cross-clamp duration), inotropic or vasodilator support, 
intubation time, death, renal failure and postoperative hospital stay (see Data 
Collection Sheet in appendix). 
All these parameters were defined according to the standard written protocols used in 
the Intensive Care Unit at the Bristol Children Hospital. We later analysed the effect of 
normoxic versus hyperoxic CPB in single and biventricular patients separately. 
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2.2.5 Proposed Biochemical Tests: 
  
Troponin I (as a myocardial damage indicators), 8- isoprostane (a marker of oxidative 
stress), alpha glutathione S-transferase [aGT] (a liver enzyme which raised levels may 
suggest liver injury), serum S100 (raised levels may indicate possible CNS insult) plus 
general inflammatory markers including complement activation C3a, serum cortisol, 
interleukin [IL] -6, -8, and -10.  
The blood samples were taken at: anaesthetic induction, 10 and 30 minutes after 
initiation of CPB, plus 10min, 4 hours and 24 hours post cessation of CPB.  
All blood samples were taken from the arterial lines.  
Each time 1ml of blood sample was used for arterial blood gas (ABG) analysis. 
Furthermore, 1ml of blood in EDTA bottle and 3ml of blood in Lithium Heparin bottle 
were stored. The EDTA and Lithium Heparin bottles were placed in a container filled 
with ice during transport to laboratory. The samples were then centrifuged at 4 
degrees Celsius for 15 minutes at 4000 revolutions per minute to isolate the plasma.  
The plasma samples were then stored in special containers using pipet and were 
immediately frozen in liquid nitrogen. They were then stored in the freezers that were 
set at -80 degrees Celsius on level 7, Bristol Heart Institute. Plasma from the EDTA 
bottle was used for C3a measurement and plasma from Lithium Heparin bottle was 
used for the analysis of other aforementioned tests. 
 
Mr Mark Ginty, an experienced laboratory technician with previous experience in 
similar blood sample analysis, measured the systemic and organ specific injury 
markers in Bristol Heart Institute’s laboratories.  
 
2.3 Primary and secondary endpoint: 
 
Primary end points are the release of troponin I and 8-isoprostane as a measurement 
of myocardiac cell damage and oxidavtive stress. Secondary endpoints include; 
release of markers of whole body inflamtory response (complement activation C3 
alpha, interleukin 6, 8 and 10), stress response (cortisol), cerebral injury (protein 
S100) and hepatic insult (alpha-glutathion S-transferase). 
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2.4 Ethical approval, research governance and indemnity: 
 
The Ethics Committee had issued an approval for this study. United Bristol Healthcare 
Trust Research and Development (R&D) sponsored the trial.   
 
2.5 Storage of records: 
 
Study records (both hardcopy and electronic) were retained in a designated and 
secure location on level 7, Bristol Heart Institute during the conduct of the trial and 
after completion.  All source documents will be retained for a period of 5 years 
following the end of the study.  Where trial-related information is documented in the 
medical records, the records are identified with a “Do not destroy before 
dd/mm/yyyy” label, the date being 5 years after the last patient was recruited for the 
trial.  
 
2.6 Research Governance Statement: 
 
This study was conducted in accordance with the Research Governance Framework 










3 - Biochemical Assays  
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3.1 Markers of systemic and organ specific injury: 
 
 
3.1.1 Cardiac Troponin-I (cTn-I): 
 
Historically, the diagnosis of acute myocardial injury has been via history taking and 
physical examination in conjunction with 12-lead electrocardiography (ECG). Later, 
serial creatine kinase isoenzyme (CK and CK-MB) measurements, and determination 
of lactate dehydrogenase (LDH) isoenzyme ratios were used to diagnose myocardial 
injury. However their popularity declined due to limitations such as lack of accuracy 
in patients with renal impairment [285, 286]. 
One set of assays focused on proteins from the troponin complex. Three troponin 
subunits regulate muscle contraction by modulating the calcium-dependent 
interaction of actin and myosin: the tropomyosin binding subunit T, the calcium-
binding subunit C, and the actomyosin ATPase inhibiting subunit I. Troponin-I exists 
in three isoforms: slow-twitch, fast- twitch, and cardiac. Cardiac troponin-I (cTn-I) is a 
26.5 kDa isoform of the muscle subunit, and is genetically and structurally distinct 
from that produced in extracardiac muscle [287, 288]. 
Cardiac troponin-T (cTn-T) and cTn-I correlate with acute myocardial injury in the 
general population, both turning positive within 6–8 h and remaining so for at least 4–
7 days [289, 290]. Spurious cTn-T elevations, similar to CK-MB, have been identified in 
patients with renal failure [291, 292]. Cardiac troponin-I however, has been shown to be 
specific for myocardial damage in the setting of renal failure, hypothyroidism, 
rhabdomyolysis, skeletal muscle injury, perioperative period, burns and cocaine 
intoxication [293-298]. Due to its high specificity, cTn-I appears to be ideally suited for 
the detection of myocardial injury and myocardial necrosis in complex clinical 
situations [290]. Measurement of cTn-I could simplify the care of patients by 





3.1.1.1 Principles Of The Procedure: 
Access Immunoassay System®; Beckman Instruments Inc, Troponin I ELISA was 
used for the measurement of troponin levels in our samples. The assay is based 
on enzyme immunoassay (ELISA) technology using horseradish peroxidase as a 
label. 25 μL of plasma is required and the hook effect is avoided by using 2-step 
assay format (30 min + 30 min). The substrate contains both 3,3’, 5,5’ 
tetramethylbenzidine (TMB) and hydrogen peroxide (H2O2) in one bottle format 
with greatly enhanced stability and sensitivity. Increasing absorbance is 
monitored at 450 nm (Figure 18). 
Results calculation is by calculating the mean of the duplicate absorbance 
determinations. A standard curve on graph paper is then constructed by plotting 
the mean absorbances of the six standards (ordinate) against the corresponding 




Figure 18 Serum Tn-I Measurement 








The isoprostanes are from eicosanoids family and are produced via tissue 
phospholipids oxidation with oxygen radicals. Isoprostanes can materialise as 
artefacts in plasma or tissue samples that have suffered prolonged oxidative 
degradation during improper storage. Under normal conditions small levels of 
isoprostanes may be detectable in the plasma and urine; however, the levels will 
significantly rise by oxidative stress [299]. 
 
One of the isoprostanes, 8-isoprostane (8-iso Prostaglandin F2α), has been 
particularly reported to have biological activity. This prostaglandin compound 
that belongs to the F2 isoprostane class is formed in vivo by the free radical-
catalysed peroxidation of arachidonic acid [300]. It has very strong renal and 
pulmonary vasoconstrictor properties [301] and is associated to causative 
mediators of hepato-renal syndrome and pulmonary oxygen toxicity [302]. 
Assessment of in vivo oxidative stress by measurement of 8-Isoprostane has 
emerged as one of the most reliable approaches that provides an essential tool to 
investigate the role of oxidative stress in the pathogenesis of human disease [303] 
  
Elevated levels are found in heavy smokers and can also be an indicator of 
antioxidant deficiency [304]. 8-Isoprostane can also be used to assess the sample 
integrity for lipid-containing specimen such as serum, plasma, and whole cell 
preparations [305]. Plasma of healthy individuals may contains modest amounts of 
8-isoprostane (40-100 pg/ml) that can increase with age [306]. 
 
3.1.2.1 Principle of the method: 
 
Cayman Chemical™ 8-Isoprostane EIA kit was used for this study. 
This assay is based on the competition between 8-isoprostane and an 8-
isoprostane- acetylcholinesterase (AChE) conjugate (8-Isoprostane Tracer) for a 
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limited number of 8-isoprostane-specific rabbit antiserum binding sites. Because 
the concentration of the 8-Isoprostane Tracer is held constant while the 
concentration of 8-isoprostane varies, the amount of 8-Isoprostane Tracer that is 
able to bind to the rabbit antiserum will be inversely proportional to the 
concentration of 8-isoprostane in the well. This rabbit antiserum-8- isoprostane 
(either free or tracer) complex binds to the rabbit IgG mouse monoclonal 
antibody that has been previously attached to the well. The plate is washed to 
remove any unbound reagents and then Ellman’s Reagent (which contains the 
substrate to AChE) is added to the well. The product of this enzymatic reaction 
has a distinct yellow colour and absorbs strongly at 412 nm. The intensity of this 
colour, determined spectrophotometrically, is proportional to the amount of 8-
Isoprostane Tracer bound to the well, which is inversely proportional to the 
amount of free 8-isoprostane present in the well during the incubation. 
 
Figure 19 Schematic of the ACETM EIA 
(Diagram from www.caymanchem.com) 
 
3.1.3 Interleukin-6 (IL-6): 
 
Unlike many cytokines interleukin-6 is both produced by and has effects on a 
broad spectrum of cell types. The range of activities include both growth 
promotion and inhibition, regulation of immunoglobulin and acute phase protein 
gene expression and induction of differentiation [307]. 
Human interleukin-6 ((h)IL-6) is a 212 (precursor), 184 (mature) amino acid 
protein with a molecular weight of 23–30 kDa (determined by SDS PAGE) which 
is N-linked glycosylated [307, 308]. Numerous cell types produce IL-6 including: B 
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and T cells and cell lines, monocytes and monocyte lines, fibroblasts, endothelial 
cells, keratinocytes, bone marrow stromal cells and several tumour cell lines. The 
IL-6 receptor is a heterodimeric molecule consisting of an 80 kDa IL-6 binding 
protein and a 130 kDa accessory molecule, which is required for the high affinity 
form (1 × 10-11 M) that can transduce signals. The IL-6 receptors have been 
found to be on a wide range of cells including B and T cells, monocytes, 
myelomas, hepatocytes, hepatomas and astrocytomas up to 10 000 per cell [308-
310]. A soluble circulating form of the 80 kDa IL-6 binding protein is able to form a 
complex with IL-6 which can then associate with the membrane bound 130 kDa 
molecule resulting in signal transduction.  
 
Investigations of IL-6 in vivo have demonstrated that its levels may alter in 
several phenomena. These include ischaemia-reperfusion experiments in some 
animal models as well as ischaemia-reperfusion injury post-transplant in human 
[311-313]. 
 
3.1.3.1 Principle of the method: 
 
Amersham Interleukin-6 [(h)IL-6] Human, Biotrak ELISA System,GE Healthcare, 
was used for the measurement of plasma IL-6 in this study. 
 
This immunometric assay is based on a solid phase ELISA, which utilises an 
antibody for (h)IL-6 bound on the wells of a microplate together with an 
antibody to (h)IL-6 conjugated to biotin and streptavidin-HRP detection. (h)IL-6 
can be measured in the approximate range of 1-400 pg/ml (0.5-20 pg/well) in 
less than 4 hours. 
 
This assay employs the quantitative ‘sandwich’ enzyme immunoassay technique. 
An antibody specific for (h)IL-6 antibody has been coated on the microplate 
provided in the kit. Samples are pipetted into the wells and the (h)IL-6, if 
present, is bound by the IL-6 immobilised antibody. A biotinylated antibody 
reagent is added to the wells and allowed to bind to any IL-6 bound by the 
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immobilised antibody in the first incubation. After washing away any unbound 
biotinylated antibody a streptavidin-HRP conjugated is added to the wells. Any 
IL-6, which was bound by both the immobilised and the biotinylated antibody 
during the first incubation, will be bound by the streptavidin conjugate. 
Following a wash to remove unbound conjugate, a substrate solution is added to 
the wells and colour develops in proportion to the amount of (h)IL-6 bound in 
the initial step. 
In addition to the samples to be tested, a series of wells are prepared using 
known concentrations of the human IL-6 standard. A curve, plotting the optical 
density versus the concentration of the standard well is prepared. By comparing 
the optical density of the samples to this standard curve, the concentration of the 
(h)IL-6 in the unknown samples is then determined. 
 
3.1.4 Alpha Glutathione S-Transferase (Alpha GST or αGT): 
 
Hepatic reoxygenation injury has been demonstrated in experimental animal 
models of rats undergoing induced hypoxia for 60 minutes followed by 25 
minutes of reflow [314]. It has also been shown that during reoxygenation of 
perfused rat liver, there is an increased oxyradical production leading to liver 
injury [315]. The alpha glutathione S-transferase ( GTs) are a group of cytosolic 
proteins that constitute from 2% to 5% of the soluble protein in hepatocytes [316]. 
 
In liver, GTs is located in the hepatocytes whereas piGTs (πGTs) is confined to 
the intrahepatic bile duct cells [317-320]. This heterogeneous GST subclass 
distribution suggests that the isoenzymes have unique in vivo functions in 
different hepatic regions and that the detection of GST subclass levels in 
biological fluids would be of significant use in monitoring the integrity of specific 
hepatic regions. 
A routine and a common way of to evaluate liver function are to measure the 
liver enzymes, alanine aminotransferase (ALT) and aspartate aminotransferase 
(AST). The disadvantage of these markers is that they are not distributed 
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uniformly throughout the liver, the periportal concentration being greater than 
the centrilobular [317]. In contrast, αGTs has been found to be equally distributed 
in both the centrilobular and periportal regions [321]. Centrilobular hepatocytes 
are very susceptible to damage in a variety of clinical conditions including 
allograft rejection [322], viral hepatitis [323], chronic active hepatitis [324], and 
hepatotoxicity [325].  
GTs in serum is very low, and as 
GTs is a very sensitive and specific biomarker of 
hepatocyte injury [326]. It is unaffected by muscle injury and other factors that can 
cause elevated transaminase levels [316]
GT 
level almost excludes acute hepatocyte injury [316]. 
3.1.4.1 Principle of the method: 
 
Biotrin High Sensitivity Alpha GST EIA Enzyme Immunoassay kit was used for 
this test. 
This is a quantitative enzyme immunoassay. The test procedure is based on the 
sequential addition of sample, enzyme-conjugate and substrate to microassay 
wells coated with anti-αGST. The resultant colour intensity is proportional to the 
amount of αGST present in the sample. The assay range is 62.5-2000ng/L. 
 
 
3.1.5 Protein S100: 
 
Hypoxia and reoxygenation are known as important mechanisms of cerebral 
injury. Sher and Hu demonstrated in an in vitro cell model that gradual 
reoxygenation after prolonged hypoxia improves neuronal survival compared 
with rapid reoxygenation and delays the manifestations of metabolic dysfunction 
[327]. Their findings are also consistent with the concept that a period of relative 
hyperoxia may contribute to hypoxia- induced neuronal injury. Stauton et al 
have also shown that hypoxemia– reoxygenation causes endothelial dysfunction 
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in intraparenchymal cerebral arterioles by impairing endothelium-dependent 
dilation of microvessels, which in turn may decrease oxygen delivery and 
increase neuronal injury [328]. 
S100, a 20 kDa glial-cell specific protein, was initially isolated from human brain 
[329]. However to date, based on structural and functional similarities, 20 
different monomers of the S100 family have been described [330, 331]. The majority 
of the S100 proteins present in dimers form and their expressions are cell-
specific. S100A1 and S100B are two S100 monomers that are highly conserved 
amongst different species [332]. They are identified as homo- (BB) and 
heterodimers (A1B) in glial cells of the central nervous system and in some 
certain peripheral cells such as melanocytes, adipocytes, Schwann cells and 
chondrocytes [333].  
 
S100 is a useful biomarker in the management of patients with cerebral insult 
such as: head trauma, perinatal asphyxia, cardiac arrest and CVA [334-337]. It is 
considered to be one of the most specific and sensible markers of cerebral injury 
after cardiac surgery and is widely used in clinical trials [338]. 
3.1.5.1 Principle of the method: 
 
The CanAg S100 EIA Kit was used to measure S100. This is a solid-phase, two-
step, non-competitive immunoassay based on two mouse monoclonal antibodies 
specific for two different epitopes expressed in S100B. The assay determines 
both S100A1B and S100BB without cross-reactivity with other forms of S100. 
Calibrators and samples are incubated together with biotinylated Anti-S100B 
monoclonal antibody (MAb) S23 in Streptavidin coated microstrips. S100B 
present in calibrators or samples is adsorbed to the Streptavidin coated 
microwells by the biotinylated Anti-S100B MAb during the incubation. The strips 
are then washed and incubated with horseradish peroxidase (HRP) labelled Anti-
S100B MAb S53. After washing, buffered Substrate/ Chromogen reagent 
(hydrogen peroxide and 3, 3’, 5, 5’ tetra-methylbenzidine) is added to each well 
and the enzyme reaction is allowed to proceed. During the enzyme reaction a 
blue colour will develop if antigen is present. The intensity of the colour is 
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proportional to the amount of S100B present in the samples. The colour intensity 
is determined in a microplate spectrophotometer at 620 nm (or optionally at 405 
nm after addition of Stop Solution). Calibration curves are constructed for each 
assay by plotting absorbance value versus the concentration for each calibrator. 
The S100B concentrations of samples are then read from the calibration curve. 
 
3.1.6 Complement 3 Alpha (C3a): 
 
Activation of the classical, alternate, or lectin complement pathways can result in 
the production of the C3a anaphylatoxin [339]. C3a has been shown to be a 
multifunctional pro-inflammatory mediator. Thus, C3a is reported to increase 
vascular permeability, to be spasmogenic and chemotactic, and to induce the 
release of pharmacologically active mediators from a number of cell types [340]. 
 
C3a production in vivo may also initiate, contribute to, or exacerbate the 
inflammatory reactions seen in ischaemia-reperfusion injury, ischaemic heart 
disease, gram-negative bacterial sepsis, trauma, ARDS, post-dialysis syndrome, 
and several autoimmune diseases [341-343]. 
 
In blood plasma or serum, once formed, the nascent C3a anaphylatoxin is rapidly 
cleaved to the C3a-desArg form by the endogenous serum carboxypeptidase N 
enzyme [344]. Thus, the quantitation of C3a-desArg in plasma should yield a 
reliable measurement of the level of complement activation that has occurred in 
the test samples under investigation. 
 
 
3.1.6.1 Principle of the method: 
 
The BD OptEIA™ Human C3a ELISA Kit was used for the quantitative 
determination of Human C3a-desArg in our study. 
The BD OptEIATM ELISA test is a solid phase sandwich ELISA (Enzyme-Linked 
Immunosorbent Assay). It utilises a monoclonal antibody specific for human C3a-
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desArg coated on a 96-well plate. Standards and samples are added to the wells, 
and any C3a-desArg present binds to the immobilised antibody. The wells are 
washed and a mixture of biotinylated polyclonal anti-human C3a antibody and 
streptavidin-horseradish peroxidase is added, producing an antibody-antigen- 
antibody “sandwich”. The wells are again washed and a substrate solution is 
added, which produces a blue colour in direct proportion to the amount of C3a-
desArg present in the initial sample. The Stop Solution changes the colour from 
blue to yellow, and the wells are read at 450 nm 
 
3.1.7 Interleukin-10 (IL10): 
 
A systemic inflammatory response can occur following various conditions 
including ischaemia-reperfusion injuries [345]. A cascade of events including pro-
inflammatory cytokine production can ultimately lead to multiple organ failure, 
and death [346]. 
 
IL-10 characteristically has inhibitory effects on pro-inflammatory cytokine 
production and physiology of individual cell types, which suggest that it could 
have potent anti-inflammatory activities in vivo.  
 
A protective role of IL-10 in experimental endotoxemia has been demonstrated. 
Inhibition of TNF production in experimental endotoxemia was observed 
following IL-10 administration in baboons and humans [347, 348]. 
 
IL-10 was identified as the cytokine produced by the TH2 subpopulation of T 
cells that inhibit the synthesis of immunostimulatory cytokines by the TH1 cells. 
Human IL-10 can be produced by B and T cells, activated mast cells, 
macrophages monocytes and keratinocytes and is expressed as a noncovalently 
linked homodimer. Human IL-10 is a 178 amino acid protein with a molecular 
weight of 18 kDa with two N-linked glycosylation sites. 
IL-10 has been shown to exhibit profound inhibitory effects on monocytes 
including down-regulation of major histocompatibility complex (MHC) class II 
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antigen expression, suppression of IL-1α and β, IL-6, IL-8, granulocyte-
macrophage colony-stimulating factor (GM-CSF), granulocyte-colony stimulating 
factor (G-CSF) and tumor necrosis factors alpha (TNFα) production. IL-10 has 
been shown to synergise with IL-2 and IL-4 to promote the proliferation of 
thymocytes. IL-10 has also been shown to act in conjunction with IL-3 and IL-4 to 
enhance the survival of mast cells.  
 
Although IL-10 has been demonstrated to play an important role in several in 
vitro phenomena, the detection of IL-10 in vivo using bioassays or 
immunoassays has been difficult. Treatment of mice with anti-IL-10 antibodies 
resulted in the reversible depletion of Ly-1+ B cells, reduced serum IgM and IgA 
levels and attenuated antibody responses to hapten antigens. These mice also 
exhibited elevated levels of circulating IgG2a and IgG2b antibodies and TNFα. 
Mice lacking the IL-10 gene locus did not display any of the above effects, 
suggesting that immune complexes may have mediated the changes observed in 
anti-IL-10 treated mice. Agents that inhibit IL-10 production include IL-4 and 
IFNγ. 
 
The suppressive effects of IL-10 on monocytes and TH1 cytokine synthesis 
suggest that IL-10 may have utility as a general suppressor of immune function. 
In endotoxin challenge models, IL-10 has shown efficacy in ischaemia-
reperfusion and burn models [349, 350]. 
 
In addition, many strategies that are used to intervene in sepsis affect IL-10 
production [351, 352] indicate an important role for this cytokine in controlling 
systemic inflammatory responses. 
 
3.1.7.1 Principle of the method: 
 
Amersham Biosciences© Interleukin-10 [(h)IL-10] Human, Biotrak ELISA 
System, GE Healthcare, was used. 
This assay employs the quantitative ‘sandwich’ enzyme immunoassay technique. 
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An antibody specific for (h)IL-10 has been coated on the microplate provided in 
the kit. Samples are pipetted into the wells along with biotinylated antibody 
reagent, and the (h)IL-10, if present, is bound by both the immobilised antibody 
and biotinylated antibody. After washing away any unbound sample proteins 
and biotinylated antibody, a streptavidin-HRP conisjugate is added to the wells. 
Any (h) IL-10 which was bound by both the immobilised and the biotinylated 
antibody during the first incubation, will be bound by the streptavidin conjugate. 
Following a wash to remove any unbound conjugate, a substrate solution is 
added to the wells and colour develops in proportion to the amount of (h)IL-10 
bound in the initial step. 
 
In addition to the samples to be tested, a series of wells are prepared using 
known concentrations of the Baculovirus-derived human IL-10 standard. A 
curve, plotting the optical density versus the concentration of the standard well, 
is prepared. By comparing the optical density of the samples to this standard 
curve, the concentration of the (h)IL-10 in the unknown samples is then 
determined. 
 
3.1.8 Interleukin-8 (IL8): 
 
IL-8 which is primarily secreted by endothelial cells and monocytes was initially 
discovered in 1987 by Yoshimura by isolating it from human monocytes and 
distinguishing from from IL-1 by its chemotactic activity [353]. It is a heparin-
binding protein precursor and a member of the CXC chemokine subfamily of 
cytokines. It contains 99 amino acids, however the mature functional protein, is 
comprised of 72 amino acids [354] Although Chemokine Nomenclature 
Subcommittee of the International Union of Immunological Societies renamed IL-8 
to CXCL8, its approved gene symbol remains IL-8 [355]. Yet, IL-8 is also known by 
a variety of names, which describe some of its activities. These names include 
NCF (neutrophil chemotactic factor), NAP-1 (neutrophil activating protein), 
MDNCF (monocyte derived neutrophil chemotactic factor), or TCF (T- 
lymphocyte chemotactic factor).  
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IL-8 has pro-inflammatory properties and primarily facilitates the neutrophil 
activation and transendothelial migration from peripheral blood into the 
inflammation or infection sites in the tissue by interacting with CXCR1 and 
CXCR2 receptors [356, 357]. Once activated, both receptors couple to G protein to 
mediate phosphoinositide-hydrolysis, intracellular Ca2+ mobilisation, 
chemotaxis, and exocytosis [358, 359].  
 
Reoxygenation of cultured hypoxic endothelial cells and monocytes induces the 
release of significantly elevated quantities of IL-8 [360, 361]. Neutrophil-mediated 
injury during reperfusion results when flowing neutrophils encounter activated 
endothelial cells expressing adhesion molecules that mediate an initial rolling 
and then firm adherence. During this process the neutrophils become activated, 
promoting chemotaxis into the ischaemic tissue [362-364]. Evidence suggests a role 
for IL-8 in the injury pattern seen after cardiopulmonary bypass. Elevated IL-8 
levels are detected in the serum measured in coronary sinus blood after 
ischaemic cardiac arrest during heart operations requiring cardiopulmonary 
bypass [365, 366].  
 
 
3.1.8.1 Principle of the method: 
 
Amersham Interleukin-8 [(h)IL-8] Human, Biotrak ELISA System, GE Healthcare, 
was used for the measurement of plasma IL-8. This assay employs the 
quantitative ‘sandwich’ enzyme immunoassay technique. An antibody specific 
for (h)IL-8 is coated on the microplate provided with the kit. Samples are 
pipetted into the wells followed by incubation with biotinylated antibody 
reagent. If present, the (h)IL-8 is bound by the immobilised antibody and the 
biotinylated antibody. After washing away any unbound sample proteins and 
biotinylated antibody, a streptavidin-HRP conjugate is added to the wells. Any 
(h)IL-8 which was bound by both the immobilised and the biotinylated antibody 
during the first incubation will be bound by the streptavidin conjugate. 
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Following a wash to remove unbound conjugate, a substrate solution was added 
to the wells and colour developed in proportion to the amount of (h)IL-8 bound 
in the initial step. 
In addition to the samples to be tested, a series of wells were prepared using 
known concentrations of the human IL-8 standard. A curve, plotting the optical 
density versus the concentration of the standard well, was prepared. By 
comparing the optical density of the samples to this standard curve, the 
concentration of the (h)IL-8 in the unknown samples was then determined 
(Figure 20). 
Figure 20 Summary of IL-8 assay protocol 






Cortisol (hydrocortisone, compound F) is a steroid hormone synthesised from 
cholesterol. It is the primary glucocorticoid produced and secreted by the 
adrenal cortex in response to adrenocorticotropic hormone (ACTH) and is the 
most abundant circulating steroid [367]. 
It is secreted with a circadian periodicity and peaks just prior to waking in the 
morning [368]. The production of glucocorticoids is increased by stress therefore 
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cortisol can be used as a biomarker of stress [369-371].  
 
Cortisol binds to two intracellular receptors, the mineralocorticoid receptor 
(MR), and the glucocorticoid receptor (GR). Of the two receptors, the MR has the 
higher affinity for cortisol. This receptor will be almost completely occupied by 
cortisol at levels too low to activate the GR[370]. 11β-Hydroxysteroid 
dehydrogenase (Type 2) (11β-HSD2) converts cortisol to inactive cortisone. This 
enzyme is expressed predominantly in mineralocorticoid target tissues including 
kidney, colon, and salivary gland where it serves to protect the MR from 
glucocorticoid excess [372]. Individuals lacking this enzyme exhibit a syndrome 
known as apparent mineralocorticoid excess which features hypertension and 
hypokalaemia [369]. 
 
The enzyme 11β-HSD1 is a key regulator of intracellular glucocorticoid levels, 
catalysing the regeneration of cortisol from cortisone [373, 374].  Cortisol strongly 
promotes adipocyte differentiation; mature visceral adipocytes express high 
levels of the glucocorticoid receptor [373, 375]. 
Cortisol can be measured in many matrices including blood, faeces, urine, and 
saliva. Serum cortisol concentrations range from about 25-800 nM (9-300 
ng/ml) and approximately 90-95% of the plasma cortisol is bound to proteins 
[376].  
 
3.1.9.1 Principle of the method: 
 
Access Immunoassay System, Beckman Coulter ™ ACETM EIA Kits was used for 
the quantitative analysis of cortisol levels in our study.  This test kit operates on 
the basis of competition between the hormone conjugate and the cortisol in the 
sample for a limited number of binding sites on the antibody coated plate. 
The sample or standard solution is first added to the microplate.  Next, the 
diluted hormone conjugate is added and the mixture is shaken and incubated at 
room temperature for one hour.  During the incubation, competition for binding 
sites takes place.  The plate is then washed removing all the unbound 
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material.  The bound hormone conjugate is detected by the addition of substrate, 
which generates an optimal colour after 30 minutes. Quantitative test results 
may be obtained by measuring and comparing the absorbance reading of the 
wells of the samples against the standards with a microplate reader at 450nm or 
650nm.  The extent of colour development is inversely proportional to the 
amount of cortisol in the sample or standard.  For example, the absence of 
cortisol in the sample will result in a bright blue colour, whereas the presence of 











 Seventy-nine cyanotic patients undergoing corrective cardiac 
surgery were randomised to receive either controlled normoxic (70-100 
mm Hg) or hyperoxic (150–200 mm Hg) CPB. (Inclusion criteria: All 
cyanotic patients who underwent congenital cardiac surgery. Exclusion 




The primary end points were the release of troponin-I (enzyme-linked 
immunosorbent assay; Access Immunoassay System; Beckman 
Instruments Inc, Fullerton, Calif) and 8-isoprostane (enzyme immunoassay 
[EIA]; Cayman Chemicals, Ann Arbor, Mich) as measurements of 
myocardial cell damage and oxidative stress. Secondary endpoint were the 
release of markers of the whole body inflammatory response (complement 
activation [C3a], ((BD OptEIA™ Human C3a ELISA)) plus interleukin [IL] 6, 
IL-8, and IL-10 ((enzyme-linked immunosorbent assay; Amersham 
Biosciences UK, Little Chalfont, United Kingdom)), and stress response 
(cortisol; Access Immunoassay System, Beckman Coulter). Cerebral injury 
was assessed by the postoperative release of protein S100 (CanAg S100 
EIA; CanAg Diagnostics AB, Goteborg, Sweden) and alpha-glutathione S-
transferase ( GT) (Biotrin High Sensitivity Alpha GST EIA Assay; Biotrin 
International, Dublin, Ireland) was used to assess hepatic cell damage.  
 
Continuous outcomes are summarised as an arithmetic mean and standard 
deviation if normally distributed or as a geometric mean or median and 
interquartile range if skewed. Categorical data are presented as actual 
counts and percentages. Skewed measures were log-transformed to 
achieve normality and the results were back transformed to the original 
scale. All the markers had skewed distributions and were analysed on the 
logarithmic scale.  
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An overall estimate, pooled over all time points, is reported. Effect sizes are 
reported as mean differences (if normally distributed) or as ratios of 
geometric means (if skewed) with corresponding 95% confidence intervals 





4.1.1 The effect of hyperoxic versus normoxic cardiopulmonary 
bypass for all recruited patients: 
 
 Seventy-nine cyanotic patients were randomised to receive either 
controlled normoxic (70-100 mm Hg) or hyperoxic (150–200 mm Hg) CPB 
(Table 2). Forty-seven patients (59%) were double ventricular and thirty-
two (41%) had functional single-ventricular pathology (Table 7).  
 
Forty patients were randomised to the normoxic and thirty-nine to the 
hyperoxic CPB group. In the normoxic group 16 patients (40%) had 
functional single-ventricular and 24 (60%) double-ventricular pathology. 
In the hyperoxic group, 16 patients (41%) were single-ventricular and 23 
(59%) double-ventricular (Table 2).  
 
All patients with double-ventricular cyanotic pathology underwent 
curative surgery. From the 32 patients with single-ventricular pathology, 
12 (37.5%) had palliative and 20 (62.5%) had final stage surgery. 
 
Overall, the median age was 438 days (interquartile range 169–1441 days) 
with 62% male. Reasons for surgery included tetralogy of Fallot (39%), 
single ventricle (41%), transposition of the great arteries and total 
anomalous pulmonary venous drainage (20%). Preoperative 
characteristics are shown in Table 2. Intraoperative and clinical outcomes 
are reported in Table 3.  
 
Categorical outcomes (death and renal failure) were not subject to 




Table 2 Baseline Characteristics for All Patients 
Variable Normoxic (n=40) Hyperoxic (n=39) 
Age in days (median (IQR)) 448 (178 – 1212) 434 (146 – 1580) 
Male (%) 26 (65) 23 (59) 
Weight in Kg (median (IQR)) 9.6 (7.5-13.9) 9.5 (6.6-15.8) 























TAPVD & TGA 
(%) 
9 (22.5) 7 (18) 
 
TOF= Tetralogy of Fallot; TAPVD= Total Anomalous Pulmonary Venous Defect; 
TGA=Transposition of the Great Arteries 
 
 





























(41 – 147) 
89.7 
(43 – 210) 
0.93† (0.77 - 1.11) 0.40 
Cross-clamp 
time (min) * 





















time (min) § 
21.5 
(2 – 191) 
19.6 
(3 – 72) 
1.12† (0.67 - 1.87) 0.66 




(6.0 – 14.0) 
8.5 
(6.5 – 12.5) 









-0.53‡ (-2.61 - 1.56) 0.62 
Dopamine 
Peak dose (μ










(6 – 256) 
28.6 
(0 – 366) 
1.19† (0.73 - 1.96) 0.48 
 
‡) Difference in means (normoxic – hyperoxic) 
†) Ratio of geometric means (normoxic:hyperoxic) 
*) Values are expressed as mean (SD) 
§) Values are expressed as geometric mean with range  
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Table 4 Descriptive results for length of hospital stay, CPB time 
and cross clamp time (All Patients) 
 


































Mean 75.26 5.766 
95% Confidence Interval for Mean Lower Bound 63.48   
Upper Bound 87.03   
5% Trimmed Mean 72.55  
Median 64.00  
Variance 1030.665  
Std. Deviation 32.104  
Minimum 34  
Maximum 178  
Range 144  














Mean 104.32 5.186 
95% Confidence Interval for Mean Lower Bound 93.88   
Upper Bound 114.76   
5% Trimmed Mean 102.16  
Median 106.00  
Variance 1263.961  
Std. Deviation 35.552  
Minimum 50  
Maximum 210  
Range 160  



























Mean 8.81 3.275 
95% Confidence Interval for Mean Lower Bound 2.12   
Upper Bound 15.50   
5% Trimmed Mean 6.50  
Median .00  
Variance 332.561  
Std. Deviation 18.236  
Minimum 0  
Maximum 63  
Range 63  














Mean 59.45 3.319 
95% Confidence Interval for Mean Lower Bound 52.77   
Upper Bound 66.13   
5% Trimmed Mean 59.05  
Median 59.00  
Variance 517.687  
Std. Deviation 22.753  
Minimum 12  
Maximum 120  
Range 108  

























Mean 16.90 2.833 
95% Confidence Interval for Mean Lower Bound 11.12   
Upper Bound 22.69   
5% Trimmed Mean 14.77  
Median 11.00  
Variance 248.824  
Std. Deviation 15.774  
Minimum 4  
Maximum 86  
Range 82  














Mean 9.55 1.159 
95% Confidence Interval for Mean Lower Bound 7.22   
Upper Bound 11.89   
5% Trimmed Mean 8.36  
Median 7.00  
Variance 63.122  
Std. Deviation 7.945  
Minimum 4  
Maximum 55  
Range 51  
Interquartile Range 4  
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Table 5 Descriptive results for length of hospital stay, CPB time and  
cross clamp time (Normoxic group) 
 






























Mean 75.07 10.229 
95% Confidence Interval for Mean Lower Bound 53.13   
Upper Bound 97.01   
5% Trimmed Mean 71.63   
Median 60.00   
Variance 1569.638   
Std. Deviation 39.619   
Minimum 34   
Maximum 178   
Range 144   














Mean 96.58 5.699 
95% Confidence Interval for Mean Lower Bound 84.79   
Upper Bound 108.37   
5% Trimmed Mean 96.31   
Median 95.50   
Variance 779.471   
Std. Deviation 27.919   
Minimum 50   
Maximum 147   
Range 97   






















Mean 11.60 5.673 
95% Confidence Interval for Mean Lower Bound -.57   
Upper Bound 23.77   
5% Trimmed Mean 9.39   
Median 0.00   
Variance 482.829   
Std. Deviation 21.973   
Minimum 0   
Maximum 63   
Range 63   














Mean 54.71 4.677 
95% Confidence Interval for Mean Lower Bound 45.03   
Upper Bound 64.38   
5% Trimmed Mean 54.79   
Median 55.00   
Variance 525.085   
Std. Deviation 22.915   
Minimum 12   
Maximum 95   
Range 83   
























r Mean 13.07 2.168 
95% Confidence Interval for Mean Lower Bound 8.42   
Upper Bound 17.72   
5% Trimmed Mean 12.52   
Median 11.00   
Variance 70.495   
Std. Deviation 8.396   
Minimum 4   
Maximum 32   
Range 28   














Mean 10.67 2.129 
95% Confidence Interval for Mean Lower Bound 6.26   
Upper Bound 15.07   
5% Trimmed Mean 8.86   
Median 7.50   
Variance 108.754   
Std. Deviation 10.429   
Minimum 4   
Maximum 55   
Range 51   





Table 6 Descriptive results for length of hospital stay, CPB time and  
cross clamp time (Hyperoxic group) 
 





































r Mean 75.44 6.105 
95% Confidence Interval for Mean Lower Bound 62.43   
Upper Bound 88.45   
5% Trimmed Mean 73.88   
Median 66.50   
Variance 596.263   
Std. Deviation 24.418   
Minimum 43   
Maximum 136   
Range 93   














Mean 112.39 8.583 
95% Confidence Interval for Mean Lower Bound 94.59   
Upper Bound 130.19   
5% Trimmed Mean 110.05   
Median 110.00   
Variance 1694.522   
Std. Deviation 41.165   
Minimum 60   
Maximum 210   
Range 150   



























r Mean 6.19 3.530 
95% Confidence Interval for Mean Lower Bound -1.34   
Upper Bound 13.71   
5% Trimmed Mean 3.99   
Median 0.00   
Variance 199.363   
Std. Deviation 14.120   
Minimum 0   
Maximum 52   
Range 52   














Mean 62.04 5.362 
95% Confidence Interval for Mean Lower Bound 50.92   
Upper Bound 73.16   
5% Trimmed Mean 62.23   
Median 63.00   
Variance 661.225   
Std. Deviation 25.714   
Minimum 0   
Maximum 120   
Range 120   
























r Mean 20.50 5.021 
95% Confidence Interval for Mean Lower Bound 9.80   
Upper Bound 31.20   
5% Trimmed Mean 17.72   
Median 12.50   
Variance 403.333   
Std. Deviation 20.083   
Minimum 5   
Maximum 86   
Range 81   














Mean 8.39 .821 
95% Confidence Interval for Mean Lower Bound 6.69   
Upper Bound 10.09   
5% Trimmed Mean 8.00   
Median 7.00   
Variance 15.522   
Std. Deviation 3.940   
Minimum 5   
Maximum 19   
Range 14   
Interquartile Range 4   
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Table 7 Preoperative and Operative Descriptive Results for Single Ventricular 








Mean age at surgery (days) 1771.5 333.64 
Mean preoperative O2 Saturation 79.41 79.74 
Mean CPB time 75.26 104.32 
Number of patients who had their 
surgery with cross clamp 
8 (25%) 47 (100%) 
Mean postoperative intubation time 16.52 49.15 
Mean aortic cross clamp time 8.81 (34.1)* 59.45 
 
 
* Figure presented in the bracket applies to only single ventricular patients who had their surgery with 








Ratio (95% CI) P-value 
Normoxic Hyperoxic 
Troponin I 
 N=37 N=38  
Pre-Op 0.019 0.017    
10 min on CPB 0.25 0.31 0.81  
30 min on CPB 0.90 0.96 0.94 
10 min Off CPB 4.75 8.34 0.57 
4 Hrs post CPB 5.67 8.5 0.67 
24 Hrs post CPB 4.19 5.8 0.72 
Test for interaction between treatment and time 0.471 
Treatment effect, pooled over all time point 0.74 (0.71-0.77) <0.01 
8-Iso-
Prostane 
 N=39 N=37   
Pre-Op 2.8 2.3 
10 min on CPB 5.75 8.71 0.66  
30 min on CPB 7.04 9.23 0.76 
10 min Off CPB 6.49 8.91 0.72 
4 Hrs post CPB 3.75 4.87 0.76 
24 Hrs post CPB 1.81 3.54 0.51 
Test for common ratio 0.71 




 N=39 N=39   
Pre-op 0.7 0.5 
10 min on CPB 0.508 0.75 0.68  
30 min on CPB 0.545 0.67 0.81 
10 min off CPB 5.57 5.95 0.93 
4 Hrs post CPB 33.9 45.1 0.76 
24 Hrs Post CPB 50.2 47.2 1.07 
Test for interaction between treatment and time 0.84 
Treatment effect, pooled over all time points 0.85 (0.81-0.89) <0.01 
IL-8 
 N=39 N=39   
Pre-op 5.2 4.5 
10 min on CPB 6.96 8.03 0.87 
30 min on CPB 7.83 9.29 0.85 
10 min off CPB 18.05 21.11 0-85 
4 Hrs post CPB 38.24 36.95 1.02 
24 Hrs Post CPB 24.69 27.33 0.91 
Test for interaction between treatment and time 0.733 
Treatment effect, pooled over all time points 0.89 (0.83-0.95) <0.01 
IL-10 
 N=39 N=39   
Pre-op 9.3 11.2 
10 min on CPB 14.01 19.28 0.72 
30 min on CPB 21.73 28.35 0.78 
10 min off CPB 132.11 227.57 0.58 
4 Hrs post CPB 98.26 118.31 0.83 
24 Hrs Post CPB 30.4 22.21 1.35 
Test for interaction between treatment and time 0.347 
Treatment effect, pooled over all time points 0.81 (0.63-1.07) 0.13 
C3 Alpha 
 N=39 N=39   
Pre-op 1485.6 1410.2 
10 min on CPB 1293.23 1313.41 1 
30 min on CPB 1345.48 1542.85 0.98 
10 min off CPB 1574.55 1818.88 0.98 
4 Hrs post CPB 1266.82 1387.72 1 
24 Hrs Post CPB 1006.4 1049.36 1 
Test for interaction between treatment and time 0.355 
Treatment effect, pooled over all time points 1 (0.98-1.01) 0.28 
Cortisol 
 N=36 N=39   
Pre-op 493.66 416.05 
10 min on CPB 281.06 296.27 1 
30 min on CPB 276.73 305.61 0.98 
10 min off CPB 242.06 313.99 0.98 
4 Hrs post CPB 199.34 301.8 0.95 
24 Hrs Post CPB 405.04 499.63 0.98 
Test for interaction between treatment and time 0.182 
Treatment effect, pooled over all time points 0.98 (0.95-1.02) 0.31 
S100 
 N=38 N=39   
Pre-op 226.4 229.5 
10 min on CPB 343.8 473.21 0.72 
30 min on CPB 660.26 703.3 0.93 
10 min off CPB 1161.39 1519.79 0.76 
4 Hrs post CPB 304.92 311.71 0.98 
24 Hrs Post CPB 141.92 209.5 0.68 
Test for interaction between treatment and time 0.028 
Treatment effect, pooled over all time points 0.81 (0.76-0.91) <0.01 
Alpha GT 
 N=38 N=39   
Pre-op 3183.75 3110.16 
10 min on CPB 3235.47  4155.51 0.78 
30 min on CPB 4298.62  4800.91 0.89 
10 min off CPB 5602.64 7245.76 0.78 
4 Hrs post CPB 7334.83 8884.85 0.83 
24 Hrs Post CPB 3678.26 4857.65 0.76 
Test for interaction between treatment and time 0.2 
Treatment effect, pooled over all time points 0.81 (0.76-0.87) <0.01 
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4.1.2 The effect of hyperoxic versus normoxic cardiopulmonary bypass on 
patients with functional single ventricular pathology: 
 
Out of seventy-nine patients who were recruited for this study, thirty-two (41%) 
had functional single-ventricular pathology (Table 7) of which, 16 patients were 
randomised to receive normoxic CPB and 16 to hyperoxic (Table 9). The mean 
CPB time for patients with single-ventricular pathology was 75.26 minutes. 
Twenty-four patients (75%) had their surgery without aortic cross-clamp and 
eight patients (25%) had their aorta cross-clamped with a mean duration of 34.1 




In the normoxic group 5 patients (31%) had palliative and 11 (69%) had final-
stage surgery. In the hyperoxic group 7 patients (44%) had palliative and 9 




In single-ventricular group, the median age was 1545 days (interquartile range 
820–2028 days) with 62.5% male. Baseline characteristics are summarised in 




Table 9 Baseline Characteristics for Patients with Single Ventricular Pathology 
 
Variable Normoxic (n=16) Hyperoxic (n=16) 
Age in days (median (IQR)) 1476 (820-2028) 1621.5 (664.2473) 
Male (%) 10 (62.5) 10 (62.5) 
Weight in Kg (median (IQR)) 13.9 (10.6-19.6) 16.1 (11.6-19.6) 
Death 1 (6.2) 1(6.2) 











Atresia/Stenosis (%) 11(69) 5(31) 
Double-Inlet AV 
Connection (%) 
2 (13) 7 (44) 
Ebstein’s Anomaly (%) 1(6) 2(13) 
Tricuspid 
Atresia/Stenosis (%) 1(6) 2(13) 






































0.93† (0.77 - 1.11) 0.97 
Cross-clamp 
time (min) * 


















time (min) §  
21.20 
(2 – 188) 
11.50 
(2-33) 
1.84† (0.67 - 1.87) 0.45 

















-0.86‡ (-3.90-2.19) 0.57 
Dopamine 
Peak dose (μ


















‡) Difference in means (normoxic – hyperoxic) 
†) Ratio of geometric means (normoxic:hyperoxic) 
*) Values are expressed as mean (SD) 
§) Values are expressed as geometric mean with range  
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Ratio (95% CI) P-value 
Normoxic Hyperoxic 
Troponin I 
 N=15 N=16  
Pre-Op 0.01 0.01    
10 min on CPB 0.15 0.29 0.53  
30 min on CPB 0.38 0.85 0.44 
10 min Off CPB 1.12 2.19 0.51 
4 Hrs post CPB 1.75 2.55 0.69 
24 Hrs post CPB 1.45 2.21 0.66 
Test for interaction between treatment and time 0.465 
Treatment effect, pooled over all time point 0.57 0.51-0.65 <0.01 
8-Iso-
Prostane 
 N=16 N=15   
Pre-Op 3.93 3.83 
10 min on CPB 6.13 8.29 0.74  
30 min on CPB 7.85 9.83 0.80 
10 min Off CPB 6.93 8.65 0.80 
4 Hrs post CPB 5.62 7.09 0.79 
24 Hrs post CPB 2.55 4.69 0.54 
Test for common ratio 0.45 
Treatment effect, pooled over all time points 0.73 0.65-0.91 0.002 
IL-6 
 N=16 N=16   
Pre-op 0.21 0.23 
10 min on CPB 1.07 1.37 0.78  
30 min on CPB 2.17 1.87 1.16 
10 min off CPB 6.43 13.22 0.49 
4 Hrs post CPB 29.51 53.27 0.55 
24 Hrs Post CPB 34.63 35.65 0.97 
Test for interaction between treatment and time 0.39 
Treatment effect, pooled over all time points 0.79 0.46-0.93 0.02 
IL-8 
 N=16 N=16   
Pre-op 4.32 3.70 
10 min on CPB 6.36 8.28 0.77 
30 min on CPB 7.25 8.57 0.85 
10 min off CPB 13.57 16.30 0.83 
4 Hrs post CPB 35.60 37.66 0.95 
24 Hrs Post CPB 15.94 21.69 0.73 
Test for interaction between treatment and time 0.9 
Treatment effect, pooled over all time points 0.83 0.78-0.87 <0.01 
IL-10 
 N=16 N=16   
Pre-op 9.87 10.01 
10 min on CPB 19.28 29.38 0.66 
30 min on CPB 27.77 56.44 0.49 
10 min off CPB 133.14 298.21 0.45 
4 Hrs post CPB 107.43 148.13 0.73 
24 Hrs Post CPB 17.25 16.45 1.05 
Test for interaction between treatment and time 0.1 
Treatment effect, pooled over all time points 0.67 0.58-1.05 0.1 
C3 Alpha 
 N=16 N=16   
Pre-op 1482.86 1788.74 
10 min on CPB 1400.23 1680.48 0.83 
30 min on CPB 1357.63 1972.52 0.69 
10 min off CPB 1578.53 1890.55 0.83 
4 Hrs post CPB 1176.13 1544.28 0.76 
24 Hrs Post CPB 1015.28 1247.92 0.81 
Test for interaction between treatment and time 0.52 
Treatment effect, pooled over all time points 0.79 0.81-0.93 <0.01 
Cortisol 
 N=14 N=16   
Pre-op 383.58 329.57 
10 min on CPB 238.49 238.82 1.00 
30 min on CPB 215.84 231.31 0.93 
10 min off CPB 211.90 230.65 0.92 
4 Hrs post CPB 325.47 492.47 0.66 
24 Hrs Post CPB 664.83 770.54 0.86 
Test for interaction between treatment and time 0.53 
Treatment effect, pooled over all time points 0.87 0.83-0.99 0.04 
S100 
 N=16 N=16   
Pre-op 162.13 147.32 
10 min on CPB 314.63 442.82 0.71 
30 min on CPB 580.59 585.87 0.99 
10 min off CPB 762.02 966.13 0.79 
4 Hrs post CPB 242.71 262.35 0.93 
24 Hrs Post CPB 115.36 167.63 0.69 
Test for interaction between treatment and time 0.1 
Treatment effect, pooled over all time points 0.82 0.66-0.91 0.002 
Alpha GT 
 N=16 N=16   
Pre-op 3198.85 2656.74 
10 min on CPB 3222.60 4210.77 0.77 
30 min on CPB 4362.81 5125.47 0.85 
10 min off CPB 5338.84 6296.62 0.85 
4 Hrs post CPB 5935.78 9290.39 0.64 
24 Hrs Post CPB 3423.56 6604.94 0.52 
Test for interaction between treatment and time 0.52 
Treatment effect, pooled over all time points 0.72 0.60-0.85 <0.01 
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4.1.3 The effect of hyperoxic versus normoxic cardiopulmonary bypass on 
patients with double ventricular cyanotic pathology: 
 
Forty-seven from a total of seventy-nine patients (59%) who were recruited for 
this study had biventricular cyanotic pathology (Table 7). 24 patients were 
randomised to the normoxic and 23 to the hyperoxic arm of this study (Table 
12). Overall, the median age was 222 days (interquartile range 40–438 days) 
with 61.7% male.  
 
All double-ventricular patients underwent curative surgery with aortic cross-
clamp. Mean aortic cross-clamp time was 59.45 minutes with minimum of 12 
and maximum of 120 minutes. The mean CPB time for patients with 
biventricular pathology was 104.32 minutes (Table 7). 
 
Baseline characteristics are summarised in Table 12. Intraoperative and clinical 




Table 12 Baseline Characteristics for Double-Ventricular Cyanotic Patients 
 
Variable Normoxic (n=24) Hyperoxic (n=23) 
Age in days (median (IQR)) 217.5 (29 – 550) 223 (74 – 434) 
Male (%) 16 (66.7) 13 (56.5) 
Weight in Kg (median (IQR)) 7.6 (3.6-9.3) 7.6 (4.7-9.8) 
Death 0 (0) 0 (0) 






















TAPVD (%) 2 (8) 2 (9) 
 
TOF= Tetralogy of Fallot; TAPVD= Total Anomalous Pulmonary Venous Defect; 
TGA=Transposition of the Great Arteries 
 
 



































0.88† (0.77 - 1.11) 0.97 
Cross-clamp 
time (min) * 
54.71 
(22.91) 

















































0.11‡ (-2.18-2.40) 0.92 
Dopamine 
Peak dose (μ


















‡) Difference in means (normoxic – hyperoxic) 
†) Ratio of geometric means (normoxic:hyperoxic) 
*) Values are expressed as mean (SD) 
§) Values are expressed as geometric mean with range 
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Ratio (95% CI) P-value 
Normoxic Hyperoxic 
Troponin I 
 N=22 N=22  
Pre-Op 0.03 0.02    
10 min on CPB 0.43 0.40 1.10  
30 min on CPB 1.88 1.25 1.48 
10 min Off CPB 19.17 20.66 0.91 
4 Hrs post CPB 18.75 19.86 0.93 
24 Hrs post CPB 10.98 10.10 1.10 
Test for interaction between treatment and time 0.7 
Treatment effect, pooled over all time point 1.1 0.93 - 1.29 0.31 
8-Iso-
Prostane 
 N=23 N=22   
Pre-Op 3.04 2.28 
10 min on CPB 5.05 9.67 0.51  
30 min on CPB 5.23 9.77 0.54 
10 min Off CPB 5.29 10.46 0.50 
4 Hrs post CPB 2.58 3.98 0.65 
24 Hrs post CPB 1.24 2.80 0.44 
Test for common ratio 0.9 
Treatment effect, pooled over all time points 0.52 0.47-0.6 <0.01 
IL-6 
 N=23 N=23   
Pre-op 0.29 0.27 
10 min on CPB 0.35 0.35 0.98  
30 min on CPB 0.22 0.25 0.87 
10 min off CPB 6.15 2.25 2.75 
4 Hrs post CPB 40.14 41.32 0.95 
24 Hrs Post CPB 65.16 61.27 1.05 
Test for interaction between treatment and time 0.46 
Treatment effect, pooled over all time points 1.15 0.87-1.48 0.3 
IL-8 
 N=23 N=23   
Pre-op 5.51 5.50 
10 min on CPB 7.37 7.43 1.00 
30 min on CPB 8.17 9.76 0.83 
10 min off CPB 22.33 26.00 0.87 
4 Hrs post CPB 39.11 34.76 1.12 
24 Hrs Post CPB 37.06 34.35 1.07 
Test for interaction between treatment and time 0.29 
Treatment effect, pooled over all time points 0.98 0.87 - 1.1 0.61 
IL-10 
 N=23 N=23   
Pre-op 13.45 12.21 
10 min on CPB 8.65 16.15 0.54 
30 min on CPB 15.59 16.16 0.95 
10 min off CPB 122.35 170.96 0.72 
4 Hrs post CPB 87.07 113.23 0.78 
24 Hrs Post CPB 32.99 33.20 1.00 
Test for interaction between treatment and time 0.6 
Treatment effect, pooled over all time points 0.79 0.66-0.95 0.01 
C3 Alpha 
 N=23 N=23   
Pre-op 1489.06 1243.19 
10 min on CPB 1046.64 1024.24 1.02 
30 min on CPB 1187.34 1219.30 0.95 
10 min off CPB 1391.82 1708.55 0.81 
4 Hrs post CPB 1277.29 1221.53 1.05 
24 Hrs Post CPB 925.24 943.06 1.00 
Test for interaction between treatment and time 0.62 
Treatment effect, pooled over all time points 0.85 0.78-1.05 0.38 
Cortisol 
 N=22 N=23   
Pre-op 582.63 480.62 
10 min on CPB 306.58 344.30 0.89 
30 min on CPB 329.73 354.34 0.93 
10 min off CPB 259.80 314.30 0.81 
4 Hrs post CPB 129.06 188.94 0.68 
24 Hrs Post CPB 283.37 297.32 0.95 
Test for interaction between treatment and time 0.68 
Treatment effect, pooled over all time points 0.85 0.78-0.93 <0.01 
S100 
 N=22 N=23   
Pre-op 286.02 265.21 
10 min on CPB 382.20 490.88 0.78 
30 min on CPB 721.49 807.65 0.89 
10 min off CPB 1707.54 2293.36 0.74 
4 Hrs post CPB 370.17 346.07 1.07 
24 Hrs Post CPB 174.64 242.67 0.71 
Test for interaction between treatment and time 0.4 
Treatment effect, pooled over all time points 0.83 0.74-0.93 <0.01 
Alpha GT 
 N=22 N=23   
Pre-op 3500.18 3855.77 
10 min on CPB 3240.35 4037.40 0.79 
30 min on CPB 4066.82 4446.05 0.91 
10 min off CPB 5815.27 8080.95 0.71 
4 Hrs post CPB 8340.08 9091.89 0.92 
24 Hrs Post CPB 3627.80 3765.82 0.95 
Test for interaction between treatment and time 0.4 
Treatment effect, pooled over all time points   0.87 0.78-0.99 <0.01 
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4.1.3.1 Effect of Normoxic Versus Hyperoxic Cardiopulmonary Bypass on 
the Release of Troponin-I in All Groups: 
 
Troponin-I was released in a time-dependent fashion as described [283, 377] By 10 
minutes after the cessation of CPB, the release of troponin levels were 
significantly higher than baseline in both groups (Table 8). The levels continued 
to rise during the 4 hours after surgery (Figure 21) and remained high (compared 
with baseline) at 24 hours. Overall, troponin-I levels were significantly higher in 
















4.1.3.2  Effect of Normoxic Versus Hyperoxic Cardiopulmonary Bypass in 
Release of Troponin-I in Patients With Functional Single-
Ventricular Pathology:  
 
By 10 minutes after stopping the CPB, troponin-I levels were significantly higher 
than baseline in both groups (Table 11). The levels peaked at 4 hours after 
surgery (Figure 22) and remained high (compared with the baseline) at 24 hours. 
Overall, troponin-I levels were significantly higher in the hyperoxic group (ratio 













4.1.3.3 Effect of Normoxic Versus Hyperoxic Cardiopulmonary Bypass on 
the Release of Troponin-I in Double-Ventricular Cyanotic Patients:  
 
After 10 minutes of stopping the CPB, Troponin-I levels were significantly higher 
than baseline in both groups (Table 14). Unlike the single ventricular group that 
levels continued to raise by 4 hours after surgery, in the biventricular group, the 
levels peaked at 10 minutes post cessation of CPB and started to decline from 
this point onwards (Figure 23). There was no evidence to suggest any statistical 
difference in release of Troponin-I between the normoxic versus hyperoxic 








Figure 23 Release of Tn-I in normoxic vs. hyperoxic 




4.1.3.4 Effect of Normoxic Versus Hyperoxic Cardiopulmonary Bypass on 
the Release of 8-Isoprostane in All Groups: 
 
The release of 8-isoprostane was also time dependent  In both groups, levels rose 
from baseline 10 minutes post initiation of CPB and remained high 10 minutes 
post coming off CPB, after which time, levels declined (Table 8). The pattern of 
response was the same in both groups (Figure 24).  
Throughout, 8-isoprostane levels were significantly higher in the hyperoxic 













4.1.3.5 Effect of Normoxic Versus Hyperoxic Cardiopulmonary Bypass on 
the Release of 8-Isoprostane in Patients With Functional Single-
Ventricular Pathology: 
 
In both groups, 10 minutes after the start of CPB, levels rose from the baseline 
(Table 11) and remained high until 30 minutes post initiation of CPB, after 
which, levels declined with a similar pattern of response in both groups (Figure 
25). Throughout, 8-isoprostane levels were significantly higher in the hyperoxic 










Figure 25 8-Isoprostane release in normoxic vs. 




4.1.3.6 Effect of Normoxic Versus Hyperoxic Cardiopulmonary Bypass on 
the Release of 8-Isoprostane in Double-Ventricular Cyanotic 
Patients: 
 
In both groups, by 10 minutes after the start of CPB, levels rose from the baseline 
and remained high until 10 minutes after coming off CPB, after which levels 
declined (Table 14). The response was similar in both groups (Figure 26). The 
pattern of change in the 8-Isoprostane serum levels was similar between 
patients with biventricular cyanotic pathology and the general study population. 
The overall 8-isoprostane levels were significantly higher in the hyperoxic group 








Figure 26 Comparison of 8-Isoprostane levels 
between normoxic and hyperoxic groups in patients 
with biventricular cyanotic pathology 
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4.1.3.7 Effect of Normoxic Versus Hyperoxic Cardiopulmonary Bypass on 
the Release of Protein S100 in All Groups: 
 
The protein S100 changes were similar in both groups. There was a rise 10 
minutes after initiation of CPB (Table 8) and it peaked at 10 minutes after 
coming off CPB (Figure 27 and Table 8). There was a significant difference in the 
release of protein S100 between the normoxic versus hyperoxic groups (ratio 















4.1.3.8 Effect of Normoxic Versus Hyperoxic Cardiopulmonary Bypass on 
the Release of Protein S100 in Patients With Functional Single-
Ventricular Pathology: 
 
The protein S100 changes were similar in both groups (Figure 28 and Table 11). 
There was a rise 10 minutes after initiation of CPB and it peaked at 10 minutes 
after coming off CPB (Table 11). There was a significant difference in release of 
protein S100 between the normoxic and hyperoxic groups (ratio 









Figure 28 Protein S100 comparison between normoxic 





4.1.3.9 Effect of Normoxic Versus Hyperoxic Cardiopulmonary Bypass on 
the Release of Protein S100 in Double-Ventricular Cyanotic 
Patients: 
 
Changes to the levels of serum protein S100 were similar in both normoxic and 
hyperoxic groups (Figure 29 and Table 14). Compared to the baseline, there was 
a rise in protein S100, ten minutes after initiation of CPB (Table 14) and it 
peaked at 10 minutes after coming off CPB. There was a significant difference in 
Protein S100 levels between the two groups. Patients with biventricular cyanotic 
pathology that were randomised to the normoxic arm had an overall lower 
protein S100 levels compared to the hyperoxic group (ratio 








Figure 29 Comparison of serum Protein S100 levels 
between normoxic vs. hyperoxic groups in patients with 




4.1.3.10 Effect of Normoxic Versus Hyperoxic Cardiopulmonary Bypass on 
the Release of Alpha GT in All Groups: 
 
There was rise in GT in both normoxic and hyperoxic groups compared to 
the baseline (Table 8). The pattern of changes was similar in both groups and it 
peaked at 4 hours post termination of CPB (Figure 30 and Table 8
GT was significantly lower in the normoxic group compared to the hyperoxic 














4.1.3.11 Effect of Normoxic Versus Hyperoxic Cardiopulmonary Bypass on 
the Release of Alpha GT in Patients With Functional Single-
Ventricular Pathology: 
 
GT in both normoxic and hyperoxic groups compared to 
the baseline (Table 11
GT peaked at 4 hours post termination of CPB (Figure 31 and Table 11
GT was significantly lower in the normoxic group comparing to the 









Figure 31 Comparison of aGT levels between normoxic 




4.1.3.12 Effect of Normoxic Versus Hyperoxic Cardiopulmonary Bypass 
on the Release of Alpha GT in Double-Ventricular Cyanotic Patients: 
 
GT levels compared to the baseline 
(Table 14 GT peaked at 
4 hours post termination of CPB (Figure 32 and Table 14 GT levels 
were significantly lower in the normoxic group in contrast to the hyperoxic 









Figure 32 Serum Alpha GT levels in normoxic vs. 






4.1.3.13 Effect of Normoxic Versus Hyperoxic Cardiopulmonary Bypass 
on the Release of Interleukin 6 (IL-6) in All Groups: 
 
As shown in Figure 33 the pattern of IL-6 release was similar in both hyperoxic 
and normoxic groups. There was an increase of IL-6 plasma levels in both groups 
compared to the baseline and it continued to increase 24 hours post cessation of 
CPB (Table 8). The hyperoxic group had a significantly higher plasma IL-6 levels 
when compared to the normoxic group (ratio [normoxic/hyperoxic] = 0.85, 95% 
















4.1.3.14 Effect of Normoxic Versus Hyperoxic Cardiopulmonary Bypass 
on the Release of Interleukin 6 (IL-6) in Patients With Functional 
Single-Ventricular Pathology: 
 
As shown in Table 11, there was an increase of IL-6 plasma levels in both groups 
compared to the baseline. The IL-6 levels in the normoxic group continued to 
increase for 24 hours post cessation of CPB. However, in the hyperoxic group 
there was a decline in the plasma IL-6 levels after 24 hours post termination of 
CPB (Figure 34 and Table 11). Overall the single-ventricular patients in the 
hyperoxic group had significantly higher plasma IL-6 levels when compared with 








Figure 34 IL-6 levels in normoxic vs. hyperoxic groups 




4.1.3.15 Effect of Normoxic Versus Hyperoxic Cardiopulmonary Bypass 
on the Release of Interleukin 6 (IL-6) in Double-Ventricular 
Cyanotic Patients: 
 
As shown in Table 14, there was an increase of IL-6 plasma levels in the 
normoxic and hyperoxic groups compared to the baseline. The IL-6 levels in both 
normoxic and hyperoxic groups continued to increase by 24 hours following 
cessation of CPB (Figure 35). The pattern of IL-6 changes in biventricular group 
was similar to the overall patients. There was no evidence to suggest any 
statistically significant difference between the normoxic and hyperoxic groups 








Figure 35 Comparison of interleukin-6 in normoxic 
vs. hyperoxic groups in patients with double-




4.1.3.16 Effect of Normoxic Versus Hyperoxic Cardiopulmonary Bypass 
on the Release of Interleukin 8 (IL8) in All Groups: 
 
As seen in Table 8, the plasma interleukin 8 showed a rise compared to the 
baseline in both groups and they both followed a similar pattern. It peaked 4 
hours post coming off CPB (Figure 36)  Overall, the hyperoxic group had 
significantly higher plasma IL-8 levels compared to the normoxic group (ratio 














4.1.3.17 Effect of Normoxic Versus Hyperoxic Cardiopulmonary Bypass 
on the Release of Interleukin 8 (IL-8) in Patients With Functional 
Single-Ventricular Pathology: 
 
As seen in Table 11, the plasma interleukin-8 showed a rise compared to the 
baseline in both groups. It peaked at 4 hours after coming off CPB (Figure 37 and 
Table 11). The pattern of changes were similar in both hyperoxic and normoxic 
groups. Single-ventricular patients showed a similar pattern to the whole study 
population regarding changes to the plasma IL-8 levels. The hyperoxic group 
had significantly higher plasma IL-8 levels compared to the normoxic group 








Figure 37 IL-8 levels in normoxic vs. hyperoxic 




           
  
4.1.3.18 Effect of Normoxic Versus Hyperoxic Cardiopulmonary Bypass 
on the Release of Interleukin 8 (IL-8) in Double-Ventricular 
Cyanotic Patients: 
 
Plasma interleukin 8 showed a rise compared to the baseline in both the 
normoxic and hyperoxic groups (Table 14) and peaked at 4 hours post coming 
off CPB (Figure 38). There was no difference in IL-8 release between the 
normoxic versus hyperoxic groups in patients with biventricular cyanotic 








Figure 38 Interleukin-8 measurements in hyperoxic 





4.1.3.19 Effect of Normoxic Versus Hyperoxic Cardiopulmonary Bypass 
on the Release of Other Inflammatory Markers (IL-10, C3a, and 
Cortisol) in All Groups: 
 
In both groups, IL-10 levels rose after the initiation of CPB and remained higher 
than at baseline (Table 8 and Figure 39). The C3a release was greatest 10 
minutes after coming off CPB and then it declined (Figure 40). In contrast, 
cortisol levels fell dramatically during surgery and remained lower than at 
baseline by 4 hours after coming off CPB (Table 8 and Figure 41).  
For the above three inflammatory markers, there were no statistically significant 
























Figure 41 Cortisol level comparisons in normoxic and hyperoxic groups in all patients 
 123 
 
4.1.3.20 Effect of Normoxic Versus Hyperoxic Cardiopulmonary Bypass 
in Release of Complement 3 alpha (C3a) in Patients With 
Functional Single-Ventricular Pathology: 
 
The levels in both groups showed an initial decline by 10 minutes after the 
initiation of CPB (Table 11). However, the normoxic group showed a further 
reduction in levels by 30 minutes following initiation of CPB. It peaked 10 
minutes post cessation of CPB then declined to below the pre-operative levels. In 
the hyperoxic group, however, the levels of C3a peaked 30 minutes post 
initiation of CPB and declined from then onwards (Figure 42 and Table 11).  In 
contrast to the C3a levels for all patients, the overall levels of plasma C3a were 
significantly higher in the hyperoxic group compared to the normoxic group in 
patients with single-ventricular pathology (ratio [normoxic/hyperoxic] = 0.87, 







Figure 42 C3a levels in normoxic vs. hyperoxic 









4.1.3.21 Effect of Normoxic Versus Hyperoxic Cardiopulmonary Bypass 
on the Release of Complement 3 alpha (C3a) in Double-Ventricular 
Cyanotic Patients: 
 
The C3a levels in both normoxic and hyperoxic groups showed a decline by 10 
minutes after the initiation of CPB compared to the baseline (Table 14). The 
levels peaked by 10 minutes after stopping the CPB (Figure 43 and Table 14). 
There was no difference in release of C3a between the normoxic and hyperoxic 









Figure 43 Measurements of C3 Alpha in normoxic vs. 










4.1.3.22 Effect of Normoxic Versus Hyperoxic Cardiopulmonary Bypass 
on the Release of Cortisol in Patients With Functional Single-
Ventricular Pathology: 
 
Cortisol levels in both groups showed a marked decrease compared to the 
baseline by 10 minutes post initiation of CPB. However at 24 hours post 
cessation of CPB the levels were higher than baseline (Table 11). In patients 
with single-ventricular pathology, the overall plasma cortisol levels were 
significantly higher in the hyperoxic group in contrast to the normoxic (ratio 









Figure 44 Comparison of cortisol release between 
normoxic vs. hyperoxic groups in patients with 





           
  
4.1.3.23 Effect of Normoxic Versus Hyperoxic Cardiopulmonary Bypass 
on the Release of Cortisol in Double-Ventricular Cyanotic Patients: 
 
The serum cortisol levels in both the normoxic and hyperoxic groups showed a 
marked drop compared to the baseline after 10 minutes following initiation of 
CPB and continued to remain low until 24 hours post cessation of CPB (Table 
14). The levels were at their lowest at 4 hours after stopping the CPB and the 
pattern of change was similar in both groups (Figure 45 and Table 14). Patients 
with biventricular cyanotic pathology that were randomised to the normoxic 
arm of this study had significantly lower cortisol levels compared to the 









Figure 45 Normoxic vs. hyperoxic plasma cortisol 







4.1.3.24 Effect of Normoxic Versus Hyperoxic Cardiopulmonary Bypass 
on the Release of Interleukin 10 (IL-10) in Patients With 
Functional Single-Ventricular Pathology: 
 
In both groups, IL-10 levels rose significantly after the initiation of CPB 
compared to the baseline (Table 11). The pattern of change was similar in both 
normoxic and hyperoxic groups (Figure 46 and Table 11). 
There was no evidence to suggest any significant difference between the 










Figure 46 IL-10 level comparisons between normoxic 










4.1.3.25 Effect of Normoxic Versus Hyperoxic Cardiopulmonary Bypass 
on the Release of Interleukin-10 (IL-10) in Double-Ventricular 
Cyanotic Patients: 
 
In both normoxic and hyperoxic groups, IL-10 levels rose significantly after the 
initiation of CPB compared to the baseline (Table 14). The levels peaked by 10 
minutes after coming off CPB and the pattern of change was similar in both 
groups (Figure 47 and Table 14). Unlike the patients with single ventricular 
pathology, there was a statistically significant difference in the serum IL-10 
changes between the normoxic versus hyperoxic patients with biventricular 








Figure 47 Interleukin-10 comparison between 
normoxic vs. hyperoxic groups in patients with 


















In this study, we demonstrated that “controlled reoxygenation” on starting CPB in 
cyanotic patients undergoing corrective cardiac surgery is beneficial and significantly 
reduces the reoxygenation injury. Normoxic CPB was indeed associated with reduced 
oxidative stress, cerebral, myocardial and hepatic injury as well as systemic 
inflammatory response compared with hyperoxic CPB. 
 
 
5.1.1 Myocardial Damage and Reoxygenation Injury: 
5.1.1.1 Assessment of myocardial injury with Troponin-I (Tn-I) 
One of the key contributors to post-operative morbidity and mortality in paediatric 
cardiac surgery is post-operative myocardial dysfunction. Compared to adults who 
undergo repair of acquired normoxic defects, the myocardial dysfunction has been 
found to be more severe in children [233, 378, 379]. Furthermore the response to inotropic 
agents in neonates is reduced when compared to adults [378, 379]. Therefore, myocardial 
function preservation in neonates during cardiac surgery is of great importance. A 
proposed strategy to prevent reoxygenation injury is to employ controlled 
reoxygenation during CBP. 
 
In this study, troponin-I and 8-Isoprostane were used as a measure to assess myocardial 
damage and reoxygenation injury.  
 
We showed that Troponin-I was significantly lower in the normoxic group versus the 
hyperoxic (p<0.01 Table 8). The breakdown of all patients into single-ventricular and 
double-ventricular showed that in single-ventricular patients, the myocardial injury 
was significantly higher in those who were randomised to hyperoxic group compared to 
the normoxic group (p<0.01 Table 11). However no difference was found between the 
normoxic versus hyperoxic groups in the biventricular patients (p=0.31 Table 14).  
 
The comparison of mean troponin-I levels between biventricular and single ventricular 
patients showed higher troponin-I levels in the biventricular patients. (Table 11 and 
Table 14). This could be explained by the fact that most of the patients with 
biventricular pathology had ventriculotomy during surgery in order to optimise the 
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ventricular outflow tract. This myocardial resection may lead to a further release of 
troponin, resulting in a higher overall troponin levels in biventricular patients 
compared to the single ventricular patients. Imura et al have also stated this when they 
reported a further release of Troponin after ventriculotomy [284]. Moreover, the mean 
CBP time was also longer in patients with biventricular cyanotic pathology (104.32 min 
vs 75.26 min) (Table 7) and all of the biventricular patients underwent cardioplegic 
arrest (compare to only 25% of the single ventricular patients who had cardioplegic 
arrest). In addition the mean X-clamp time was lengthier in the biventricular group 
(59.45 min) compared to the 25% of the single-ventricular patients who had their aorta 
X-clamped (34.1 min) (Table 7). There is evidence that X-clamping can lead to a further 
cardiac insult which has a direct correlation to the X-clamp duration [380].  All these 
additional releases of troponin-I may hinder accurate assessment of myocardial injury 
solely related to hyperoxic injury. A larger sample size in biventricular group may be 
needed in order to demonstrate a more accurate finding regarding release of Troponin-I 
as a result of hyperoxic cardiopulmonary bypass. 
 
5.1.1.2 Oxidative stress assessment with 8-Isoprostane 
 
8-Isoprostane plasma levels are now considered a reliable method to assess oxidative 
stress. They are therefore a valuable biomarker to study the effects of oxidative injury in 
vivo [303]. Assays of 8-Isoprostane have revealed a role of free radicals and oxidant 
injury in a wide variety of pathological conditions, including ischaemia-reperfusion 
insult [303, 381-384]. It has been shown to be a suitable marker to measure the extent the 
oxidant stress has affected the myocardium during myocardial infarction [385, 386] as well 
as being a quantitative marker for oxidant stress during coronary reperfusion [387].  
 
In this randomised trial, we showed that 8-Isoprostane was significantly higher in the 
hyperoxic group compared to the normoxic group (p<0.01, Table 8). This applied to 
both single ventricular and biventricular patients (p=0.002, Table 11 and p<0.01, Table 
14). The increased 8-Isoprostane levels in the hyperoxic group suggest the direct effect 
of CPB oxygen levels on reperfusion injury. This finding corresponds with earlier 
reports indicating oxidative injury associated with hyperoxic CPB [388]. It is now evident 
that oxidative stress is a major part of the cellular mechanism that can result in 
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myocardial damage [385-387, 389]. Allen and associates demonstrated that cyanotic infants 
undergoing corrective cardiac surgery had a better antioxidant reserve capacity with 
lower levels of oxygen[14]. Similar findings were also reported by Bulutcu and co-
workers [280].  
The most common preoperative stress in paediatric cardiac patients is hypoxia 
(cyanosis) [378, 379]. Cyanotic heart is more vulnerable and less tolerant to subsequent 
surgical ischaemia than the normoxic heart [2, 5, 233, 378, 379, 390]. Moreover, cyanosis leads 
to myocardium having fewer endogenous antioxidant reserves and now there is 
gowning evidence (experimental and clinical) that this can make the immature cyanotic 
heart more venerable to oxygen induced injury when oxygen is restored [1, 4, 8]. 
Therefore, there are major concerns that reoxygenation injury could occur with the 
introduction of high levels of oxygen that can ultimately lead to cell membrane 
degradation through lipid peroxidation [1, 9]. 
 
Corno and colleagues [391], as well as some others, have documented experimentally that 
a reoxygenation injury does occur after a hypoxic insult [1, 4, 8, 233, 392]. Hirschi et al, in a 
retrospective analysis demonstrated that out of 102 neonates with respiratory failure 
supported with extracorporeal membrane oxygenation (ECMO), 8 patients developed 
severe myocardial dysfunction that was noted shortly after onset of bypass. The 
neonates in the cardiac dysfunction group were more hypoxic than the others [393]. 
Bandali and co-workers in their study, randomly allocated Yorkshire piglets to 
normoxia or hyperoxia under general anaesthesia. They showed that hyperoxic piglets 
suffered significant reductions in myocardial contractility and blood pressure. They 
concluded that in new-borns hyperoxia triggers oxygen free radical-mediated 
membrane injury together with an inability of the new-born’s heart to up-regulate its 
antioxidant enzyme defences, leading to an impaired myocardial function and 
haemodynamics [394]. 
Work in the new-born pig heart by Ihnken and colleagues [10, 395] addressed the effects 
of hyperoxia on myocardium after a period of acute hypoxia or ischaemia and identified 
the development of significant myocardial dysfunction. It is worth noting that clinical 
evidence in children with acyanotic congenital heart disease also shows that hyperoxia 
decreases cardiac and stroke indices [396] 
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5.1.2 Lower Protein S100 in Normoxic CPB Suggests Less Cerebral Injury 
Compared to Hyperoxic CPB: 
 
In our randomised trial, we assessed cerebral injury by measuring the serum protein 
S100. Protein S100 is considered one of the most specific and sensible markers of 
cerebral injury after cardiac surgery and is widely used in clinical trials [338]. 
We demonstrated that serum protein S100 was significantly higher in the hyperoxic 
group compared to the normoxic (Table 8) with values that peaked 10 minutes after 
cessation of CPB. S100 in both groups returned to preoperative levels 24 hours after the 
operation (Figure 27). This applied to both single (p<0.01 Table 11) and biventricular 
patients (p<0.01 Table 14). These findings suggest a less detrimental effect of normoxic 
CPB on the brain when compared to hyperoxic CPB. In support of our findings, there is 
clinical evidence of the effects of reoxygenation injury on cerebral function reported by 
Matheis and colleagues [397]. In their observational study, the authors demonstrated that 
uncontrolled hyperoxic reoxygenation on CPB for surgical correction of congenital heart 
defects was associated with higher S100 levels in cyanotic infants compared with 
acyanotic patients undergoing comparable operations. 
 
In recent years, hypoxia and reoxygenation have emerged as very important 
mechanisms of cerebral injury. Several studies have indicated that hyperoxia 
exacerbates post-ischaemic reperfusion injury in brain as well as kidney and 
myocardium [19, 398-401]. Among patients admitted to the ICU following resuscitation from 
cardiac arrest, arterial hyperoxia was independently associated with increased in-
hospital mortality compared with either hypoxia or normoxia [402]. In past few years, 
experimental studies revealed that neonates suffering from respiratory distress who 
were treated with higher levels of oxygen in Neonatal Intensive Care Units, developed 
oxidative and nitrative stress. This led to an increased neuronal and oligodendroglial 
apoptosis in the developing brain [403-405] 
 
In an animal study, Zwemer et al examined the effects of normoxic (FiO2 = 0.21), versus 
hyperoxic (FiO2 = 1.0) resuscitation on the neurological outcome following 9 minutes of 
normothermic cardiac arrest. They showed hyperoxically resuscitated dogs sustained 
significantly worse neurological deficit at 12 and 24 hours than the normoxically 
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resuscitated ones. They concluded that hyperoxic FiO2s could contribute to a further 
exacerbation of neurological dysfunction [401]. 
Kurul et al similarly in a separate study have indicated that exposure to hyperoxia in 
infant rats leads to extensive apoptotic degeneration in the cortex and white-matter of 
the developing brain [406]. In a different study, Yis et al studied the effects of high oxygen 
on brain tissue. They examined Wistar rat pups, which were exposed from birth until 
day 5 to 21% (normoxic) or 80% (hyperoxic) oxygen. They reported that neuronal 
densities of the different areas of the brain were significantly decreased in the 
hyperoxic group and that hyperoxia induced cell death in the developing rat brain. They 
have claimed that this may be one of the important mechanisms that cause motor and 
cognitive impairment in later life of premature infants [407]. 
Diringer and co-workers used positron emission tomography (PET) to study the impact 
of hyperoxia on patients with acute severe traumatic brain injury. They found that 
hyperoxia does not increase oxygen utilisation and has no improvement on cerebral 
oxygen metabolic rate [408]. Guo et al reported that astrocyte viability was greatly 
decreased by hyperoxia compared with normoxic controls in an in vitro model of 
hypoxia-reoxygenation [409]. Sher and Hu [327] also showed in an in vitro cell model that 
gradual reoxygenation after prolonged hypoxia improves neuronal survival compared 
with rapid reoxygenation and delays the manifestations of metabolic dysfunction. Their 
findings are also consistent with the concept that a period of relative hyperoxia may 
contribute to hypoxia-induced neuronal injury. Similarly, Stauton and co-workers have 
shown that hypoxia–reoxygenation causes endothelial dysfunction in intraparenchymal 
cerebral arterioles by impairing endothelium-dependent dilation of micro-vessels, 
which in turn may decrease oxygen delivery and increase neuronal injury [328]. 
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5.1.3 Serum Alpha GST Assay Suggests Less Hepatic Injury in Normoxic CPB 
when Compared to Hyperoxic CPB: 
 
In this study liver injury was assessed by measurements of the plasma Alpha 
Glutathione S-Transferase GTs).  
 
GTs are a group of cytosolic proteins that constitute up to 2-5% of the soluble 
protein in hepatocytes [316]
GT is a very sensitive and 
specific biomarker of hepatocyte injury [326]. It is unaffected by muscle injury and other 
factors that can cause elevated transaminase levels [316] GT level indicates 
hepatocyte injury GT level 
can almost exclude acute hepatocyte injury [316]. 
 
Our results revealed that in both single ventricular and biventricular patients, the GT 
levels were significantly higher in the hyperoxic group compared to the normoxic group 
(p<0.01 Table 11 and Table 14). The levels peaked by 4 hours post termination of CPB 
in both groups (Figure 31 and Figure 32) 
 
Hepatic reoxygenation injury has been demonstrated in experimental animal models of 
rats undergoing induced hypoxia for 60 minutes followed by 25 minutes of reflow[314]. It 
was reported that during reoxygenation of perfused rat liver, there was an increased 
oxyradical production leading to liver injury [315]. Caraceni et al reported that there is a 
correlation between liver reoxygenation injury and oxygen free radical (OFR) 
generation. They demonstrated this by submitting rat hepatocytes to 2.5 hours of 
anoxia followed by 2 hours of reoxygenation. From this, they isolated liver parenchymal 
cells that generated measurable amounts of superoxide anions [410]. In a different study, 
Bhogal and co-authors demonstrated that endogenous reactive oxygen species (ROS) 
production by mitochondria and nicotinamide adenine dinucleotide phosphate oxidase 
(NADPH-oxidase) could trigger human hepatocyte apoptosis and necrosis during 
hypoxia and hypoxia-reoxygenation, which may therefore play an important role in 
hepatic injury [411]. Jaeschke et al concluded that ischaemia-reperfusion injury, even in 
normothermic level, is an important determinant in the pathogenesis of liver damage 
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occurring during surgical procedures [412]. Rogers et al have reported; an early increases 
in 5-lipoxygenase (5-LOX) and cyclooxygenases-2 (COX-2) protein levels as well as 
increases in total hydroxyeicosatetraenoic acid (5-HETE) and prostaglandin levels in 
the liver tissues of hyperoxia-exposed pups. They indicated that exposure to higher 
levels of oxygen in newborn mice alter the hepatic eicosanoid metabolism which could 
play a role in hyperoxic liver injury [413].  
  
There is little in the literature about liver injury in cyanotic patients undergoing 
corrective cardiac surgery. Ascione et al from Bristol Heart Institute, in a randomised 
trial, demonstrated higher serum levels of ALT and AST post coronary artery bypass 
graft (CABG) using cardiopulmonary bypass machine versus off pump CABG. One can 
conclude that the CPB machine on its own can have detrimental effect on the liver. 
However in our study, there was clearly a significant difference in serum Alpha GST 
levels between the normoxic and hyperoxic groups suggesting that hyperoxic CPB can 
have a more severe detrimental effect on the liver compared to normoxic. 
 
To the best of our knowledge, this represents the first clinical evidence of a reduced 
hepatic injury when a strategy of controlled reoxygenation CPB is adopted in cyanotic 
children undergoing cardiac surgery. 
 
5.1.4 Systemic Inflammatory and Stress Response Assessment in Normoxic vs 
Hyperoxic CPB:  
 
A systemic inflammatory response can occur following various events including 
reperfusion injuries [345]. A devastating consequence of reperfusion is the development 
of remote organ injury and Multi Organ Dysfunction Syndrome (MODS) [414]. Some of the 
risk factors for MODS is CPB and aortic cross-clamping [415]. This can lead to pulmonary, 
hepatic, renal, gastrointestinal, myocardial and CNS dysfunction [416]. Nevertheless it 
might be possible to minimise these injuries with a controlled reoxygenation strategy.  
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In this randomised trial we studied the systemic inflammatory response by measuring 
the plasma levels of interleukin-6 (IL-6), interleukin-8 (IL-8), Complement C3 alpha 
(C3a), Interleukin-10 (IL-10) and cortisol. 
5.1.4.1 Release of Lower Levels of Interleukin 6 (IL-6), Interleukin 8 (IL-8) and 
Complement C3 alpha (C3a) in Normoxic Cardiopulmonary Bypass Group: 
 
In this trial we found that there was a rise in IL-6, IL-8 and C3a post initiation of 
cardiopulmonary bypass. This confirmed the previous reports on IL-6 and IL-8 
liberation during CPB [417-420]. We first looked at all patients and found that the 
normoxic group had an overall lower IL-6 and IL-8 levels compared to the hyperoxic 
group (p <0.01 Table 8). Our results confirmed the work of Bulutcu et al, who 
demonstrated cyanotic patients undergoing corrective surgery with FiO2 of 0.21 (21%) 
had a lower level of IL-6 compared to CPB with FiO2 of 1.0 (100%) [280]. However we did 
not detect any difference in the release of C3a between normoxic versus hyperoxic 
groups for all patients (p=0.25 Table 8). 
We then looked at patients with single ventricular and double ventricular pathology 
separately.  We found that patients with single ventricular pathology in the normoxic 
group also had a lower IL-6 (p<0.01) and IL-8 (p<0.01) levels compared to the 
hyperoxic group (Table 11). Interestingly, we also found that the release of C3a was 
lower (p<0.01 Table 11) in patients with single ventricular pathology who were 
randomised to the normoxic arm of this study. However no difference in IL-6, IL-8 and 
C3a levels was identified in patients with biventricular pathology (p=0.3, p=0.61 and 
p=0.38 Table 14).  
This discrepancy in IL-6, IL-8 and C3a findings between single ventricular and double 
ventricular patients could be explained by the fact that the mean CPB time in double 
ventricular patients was longer compared to the mean CPB time in single-ventricular 
patients (Table 7). Moreover only 25% of the patients in the single-ventricular group 
had their aorta cross-clamped (mean  cross calmp time = 34.1 min.) and the other 75% 
had their surgery with out cross clamp. In contrast, all patient in the biventricular group 
had their surgery with the aorta cross-clamped (mean X-clamp time = 59.45 min.) 
(Table 7). It is arguable that longer CPB and cross clamp time in the biventricular group 
can further trigger systemic inflammatory response and lead to an additional release of 
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IL-6, IL-8 and C3a. This may make the assessment of increased levels of IL-6, IL-8 and 
C3a purely related to normoxic vs. hyperoxic CPB less accurate. A larger sample size 
may be able to support this theory. 
 
When we earlier reported our preliminary results for a smaller sample size (the first 67 
patients of this study) [3], although we showed higher levels of IL-6 and IL-8 for the 
hyperoxic group, we did not find any statistically significant difference. In this research 
however, not only have we confirmed our earlier findings by showing higher levels of 
IL-6 and IL-8 in the hyperoxic group, but we have also shown that these findings are 
statistically significant (Table 8). This could be the result of 12 additional patients to 
earlier sample size (79 compared to 67), which gives a higher power for further 
statistical analysis. 
 
Interleukin 6 (IL-6) is produced by several kinds of cells, such as macrophages, 
fibroblasts, lymphocytes T & B as well as endothelial cells, vascular smooth muscle cells 
and renal mesangial cells [421-425]. It is primarily involved in the regulation of immune 
and inflammatory responses [426]. It functions not only as a B and T-cell–stimulating 
agent [423, 427], but also as a hepatocyte-stimulating factor inducing the production of a 
series of acute-phase proteins [428]. Elevated levels of serum IL-6 have been 
demonstrated in inflammations resulting from injuries induced by reperfusion post 
hypoxia/ischaemia [426, 429-431]. Some studies suggest that the amount of increase in the 
IL-6 levels observed after insult may be related to the extent of injury[432]. There is now 
good evidence that hypoxia-reperfusion leads to a significant increase in the expression 
of IL-6 in many organs including the brain [433], hind limb [434], gut [435], kidneys [426] and 
myocardium [436]. Progression of myocardial dysfunction following cardiac hypoxia-
reperfusion insult could be attributed to the IL-6 derived from the injured cardiac 
myocytes [437]. Yamauchi-Takihara et al showed that the incubation of rat cardiac 
myocytes under hypoxic conditions for 4 hours induced a significant increase in the 
production of IL-6 compared with normoxic conditions. Furthermore, 2 hours of 
hypoxic stress followed by reoxygenation for 2 hours, significantly augmented the 
production of IL-6 by cardiac myocytes [437]. In a different study, Finkel et al reported 
the negative inotropic effect of several recombinant cytokines, including IL-6, on the 
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hamster papillary muscle. They stated that the direct negative inotropic effect of 
cytokines is mediated through a myocardial nitric oxide synthase [438].  
Hypoxic stress and its association with augmented IL-6 production in cardiac myocytes 
would support the role of IL-6 not only as a possible mediator in neutrophil migration 
and activation but also in progression of myocardial dysfunction following hypoxia-
reperfusion injury [437].  
 
Interleukin-8 (IL-8) is also another proinflamatory mediator, which belongs to a family 
of chemotactic cytokines and has been described as a neutrophil/ T cell activating 
protein [439-442]. It is produced in response to ischaemia-reperfusion injury [443, 444] and 
there is a strong correlation between IL-8 expression and myocardial injury from 
oxidative stress [441]. IL-8 production is also detected after reperfusion of different 
hypoxic tissues such as lung, kidney and brain [208, 366, 445-447]. It stimulates the binding 
activity of CD11b/CD18 on human neutrophils and thus plays a critical role in the 
neutrophilic invasion into the damaged tissue [448]. Neutrophils have critical 
involvement in injuries induced by reperfusion. It has been suggested that the essential 
mechanism of neutrophilic invasion into areas damaged by ischaemia/hypoxia is by 
attachment of neutrophils onto endothelium through adhesion molecules and migration 
by chemotactic factors [449]. Boyle et al provided evidence that inhibition of IL-8 
prevents the extension of myocardial injury after reperfusion [441]. 
 
Increased levels of complement 3 alpha may also be seen as a response to reperfusion 
injury [450]. Reperfusion injury can result in release of complement C3 in various organs, 
such as myocardium, lungs, kidney, intestine and striated muscle [416, 451-454]. There are 
numerous studies that have reported that the effects of reperfusion injury have been 




5.1.4.2 Higher Levels of Interleukin 10(IL-10) in the Hyperoxic CPB Group With 
Biventricular Pathology and the Implications of This on Inflammatory 
Response: 
 
In this randomised study we showed that IL-10 levels increase after CPB. This confirms 
the findings of Seghaye et al [459]. Although the IL-10 levels were higher in the hyperoxic 
arm for all patients and those with single ventricular pathology, we did not find any 
statistically significant differences (p=0.13 and p=0.1 respectively; Table 8 and Table 
11). However in the biventricular group the overall IL-10 levels were higher in the 
hyperoxic arm compared to the normoxic arm, which was statistically significant 
(p=0.01 Table 14). 
 
IL-10 plays a complex role in the immune system. The major activities of IL-10 are to 
inhibit macrophages from producing cytokine and to suppress their accessory functions 
during T-cell activation. IL-10 also inhibits IL-1 and TNF production. This plays a crucial 
role to the anti-inflammatory activities of IL-10 [345, 460, 461]. Therefore IL-10 is widely 
considered as an immunosuppressive and anti-inflammatory cytokine. Hess et al 
reported that administration of exogenous IL-10 decreased pulmonary complications 
associated with reperfusion injury after repair of thoraco-abdominal aortic aneurysm 
(TAAA) [349]. There are also reports that endogenous interleukin-10 has a protective 
effect against early lung reperfusion injury [462]. 
Engles et al, in an animal study, showed a lower TNF-α rise in rats that had ischaemia-
reperfusion with exogenous IL-10 versus ischaemia-reperfusion alone. They reported 
that exogenous IL-10 attenuated both local and distant organ injury after hind-limb 
ischaemia-reperfusion [463]. 
Yang et al in separate study subjected wild-type and IL-10–deficient mice to myocardial 
ischaemia-reperfusion. They reported a significant production level of IL-10 in wild-
type mice at 2 to 6 hours post myocardial reperfusion. The genetic deletion of IL-10 
augmented the infiltration of neutrophil into the reperfused tissues at 6 hours post 
reperfusion and resulted in a larger size infarct and myocardial necrosis. Additionally, 
in the absence of IL-10, there was an enhancement of the overall inflammatory 
response. They stated that following 24 hours of reperfusion, in the IL-10–deficient 
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mice, the mortality rate was 75%, whereas no mortality was associated with the wild-
type mice. They concluded that endogenous IL-10 inhibits the production of TNF-α as 
well as NO, and serves to protect the hypoxic-reperfused myocardium [464]. 
Various other studies have demonstrated a direct correlation between endogenous IL-
10 levels and the severity of insult to the body (systemic inflammation) [465-472]. This is 
possibly a mechanism to minimise the extent of inflammatory response. 
 
The findings of our study indicate the possibility that hyperoxia induces further insult to 
the body compared to normoxia and therefore the body compensates by generating 
higher levels of IL-10 to minimise the inflammatory damage. Further studies may have 
to be carried out to confirm this conclusion. 
It is worth considering that a study with a larger sample size could demonstrate results 
with a significant statistical difference in patients with single ventricular pathology too.  
 
5.1.4.3 Measurement of Serum Cortisol Levels in Normoxic versus Hyperoxic 
Cardiopulmonary Bypass Groups: 
 
The production of cortisol, a primary glucocorticoid secreted by the adrenal cortex is 
increased by stress; therefore, cortisol may be used as a biomarker of stress [369-371]. 
Increased cortisol levels may be seen as a response to reperfusion injury [414, 415, 450, 473, 
474] and it has been reported that the magnitude and duration of the hormonal (cortisol) 
response to stress correlate with the extent of the injury [475]. 
 
In this randomised trial we demonstrated that; patients with single ventricular and 
double ventricular pathology who were randomised to the hyperoxic arm of this study, 
had higher levels of cortisol when compared to the normoxic group. (p=0.04, p<0.01, 
Table 11 & Table 14).  
 
In general, we showed a rise in biochemical markers for systemic inflammatory 
and stress response following initiation of CPB in cyanotic children. This corresponds 
with previous studies indicating similar inflammatory and stress response during 
paediatric cardiac surgical procedures [417, 476-478]. In addition to that, we also showed 
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that the overall inflammatory response was higher in the hyperoxic group. This was 
more noticeable in the single-ventricular patients.  
5.2 Clinical Implication and Conclusion: 
 
The above findings clearly signify the beneficial effects of normoxic versus hyperoxic 
CPB on the heart, brain and liver as well as inflammatory and systemic stress response 
in cyanotic patients undergoing corrective cardiac surgery. These findings were more 
prominent in patients with single ventricular pathology. One may conclude that single 
ventricular patients may even get a greater benefit from the advantages of normoxic 
CPB. This argument can be supported by the fact that IL-6, IL-8, C3 alpha, and Troponin-
I were all lower in single-ventricular cyanotic patients who were randomised to 
normoxic group when compared to hyperoxic. This may potentially have an important 
implication on the surgical outcome of single-ventricular patients.  
 
The findings of Finkel et al [438], Yamauchi-Takihara et al [437] and Hovels-Gurich et al 
[417], that showed IL-6 and IL-8 had a negative inotropic effect on myocytes as well as 
properties leading to myocardial dysfunction. Lower Tn-I levels as well as IL-6 and IL-8, 
in the normoxic group, may support the argument that normoxic CPB can have a 
reduced detrimental effect on the myocardium in patients with single-ventricular 
pathology. 
 
We earlier reported our preliminary results for a smaller sample size (67 patients) [3]. In 
that paper we compared normoxic to hyperoxic CPB for cyanotic patients undergoing 
corrective cardiac surgery. However, we did not carryout a further sub-analysis to 
compare the single and double ventricular pathology separately. Interestingly in our 
earlier report, we did not find any statistically significant difference in the release of 
inflammatory markers (IL-6, IL-8, IL-10, C3a and cortisol) between normoxic and 
hyperoxic groups. However, in this study we have demonstrated differences in some of 
the inflammatory markers in the normoxic versus hyperoxic groups that are statistically 
significant. This discrepancy in results could be explained by a higher number of 
patients in this study (79 patients) versus the earlier report (67 patients), which adds 
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more statistical power to this research. It may be possible that with a larger sample size, 
further differences could be demonstrated in the normoxic versus hyperoxic CPB. 
 
This randomised trial provides direct evidence that an unintended oxygen-mediated 
injury occurs in cyanotic patients with the initiation of CPB, resulting in myocardial, 
cerebral, and hepatic injury as well as triggering systemic inflammatory response. Using 
a novel and simple CPB strategy of controlled reoxygenation can reduce the risk of 
reoxygenation injury. This strategy is simple and can be incorporated at no additional 
risk into the operative management, as long as the perfusionist is familiar with the 
technique and the equipment is appropriate. It does not interfere with the surgical 
procedure and, by limiting oxidative stress and reoxygenation injury in this very high-
risk group of patients, it might lead to a reduction in morbidity and mortality. 
 
5.3 Limitations: 
Although a sample size of 40 patients per group was calculated to detect an effect size of 
0.5 or more with 90% power for this study, however a larger sample size could have 
provided results with more certainty particularly with regards the releas of cardiac 
troponin I and inflamatory markers in the biventricular group. One other limitation of 
this study was the lack of assessment of these patients for clinical outecomes such as 
survival, assessment of myocardial function and symptom evaluation (such as NHYA 
classification). 
 
However, this trial provides a solid foundation to further explore the clinical outcomes 
such as survival, ventricular function, growth and cardio-repiratory symptoms (NYHA) 
in cyanotic patients undergoing cardiac surgery with normoxic versus hyperoxic 
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Pre-operative oxygen saturation (single and double ventricular) 
















Mean 81.06 1.890 
95% Confidence Interval for Mean Lower Bound 77.03   
Upper Bound 85.09   
5% Trimmed Mean 81.35   
Median 82.50   
Variance 57.129   
Std. Deviation 7.558   
Minimum 65   
Maximum 90   
Range 27   
Interquartile Range 10   
Skewness -.317 .564 













Mean 78.08 2.064 
95% Confidence Interval for Mean Lower Bound 73.81   
Upper Bound 82.35   
5% Trimmed Mean 78.58   
Median 80.50   
Variance 102.254   
Std. Deviation 10.112   
Minimum 55   
Maximum 90   
Range 37   
Interquartile Range 16   
Skewness -.797 .472 

















Mean 77.75 1.797 
95% Confidence Interval for Mean Lower Bound 73.92   
Upper Bound 81.58   
5% Trimmed Mean 77.89   
Median 80.00   
Variance 51.667   
Std. Deviation 7.188   
Minimum 65   
Maximum 88   
Range 23   
Interquartile Range 15   
Skewness -.394 .564 













Mean 81.48 1.116 
95% Confidence Interval for Mean Lower Bound 79.16   
Upper Bound 83.79   
5% Trimmed Mean 81.59   
Median 82.00   
Variance 28.625   
Std. Deviation 5.350   
Minimum 70   
Maximum 91   
Range 21   
Interquartile Range 7   
Skewness -.416 .481 
















pO2 at start of CPB 53.21 166.34 >0.001 
pO2 5 min post CPB 65.13 202.47 >0.001 
pO2 10 min post CPB 73.97 197.17 >0.001 
pO2 30 min post CPB 115.55 172 >0.001 















Hct at Induction 44.16 45.38 0.50 
Hct 10 min post CPB 28.52 28.43 0.94 




Oxygen Partial Pressure During Cardiopulmonary Bypass in Single-Ventricular 





















pO2 at start of CPB 55.4 167.87 >0.001 
pO2 5 min post CPB 63.73 169.6 >0.001 
pO2 10 min post CPB 65.87 171.8 >0.001 
pO2 30 min post CPB 114.4 155.67 0.001 
pO2 immediately post CPB 
off 































Hct at Induction 47.42 49.20 0.47 
Hct 10 min post CPB 31.44 33.02 0.35 







Oxygen Partial Pressure During Cardiopulmonary Bypass in Double Ventricular 























pO2 at start of CPB 51.78 165 >0.001 
pO2 5 min post CPB 66 231.47 >0.001 
pO2 10 min post CPB 79.04 216.2 >0.001 
pO2 30 min post CPB 116.3 184.25 >0.001 
































Hct at Induction 41.90 42.73 0.72 
Hct 10 min post CPB 26.49 25.24 0.25 
Hct 30 min post CPB 26.87 25.36 0.18 
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